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ABSTRACT
Abstract
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Section I
Abstract
Breast cancer is the third most common tumor in the world and represents 
9% of global cancer burden. In India, breast cancer is the second common cancer 
in women after cervical cancer and has of late replaced cervical cancer as the 
leading site of cancer among women in Indian cities. Preliminary indications 
point towards an increasing trend in the occurrence of breast cancer amongst 
Kashmiri population. However, authentic data with regard to prevalence is almost 
non-existent in the state of Jammu and Kashmir. To our knowledge, this is the 
first attempt to examine the epidemiological distribution of different cancer types 
with particular emphasis on breast cancer in the whole valley. The source of our 
data include cancer registry in the Department of Radiation Oncology, Sheri-
Kashmir Institute of Medical Sciences, Srinagar, and Department of Radiation 
Oncology, SMHS, Srinagar during Jan 2002 to Dec 2006. A total of 6943 cases 
registered between 1st January 2002 to 31st December 2006 comprised of 4345 
males and 2598 females. The age standardized incidence rates were 34.9 per 
100,000 for males and 24.8 per 100,000 for females. Oesophagus was the leading 
site of cancer in both the sexes (male ASR 11.2; female ASR 8.3) followed by 
lung (ASR 6.5), brain (ASR 2.2), head and neck (ASR 2.2) in males and breast 
(ASR 5.2), skin (ASR 1.6) and rectum (ASR 0.95) in females. The incidence of 
cervical cancer turned out to be surprisingly low in Kashmiri women as 
compared to other Indian Registries quite contrary to the pattern in rest of the 
country. Our studies imply that cancer incidence was significantly lower and 
cancer patterns were markedly different in Kashmir. The observed cancer pattern 
indicates that awareness campaigns, life style and dietary habit changes, tobacco-
control measures and early detection of breast cancer are very important for 
cancer control in this cohort of population.
Abstract
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Section II
Abstract
Environmental and genetic factors are attributed to explain the spectrum of 
geographical and ethnic variations in the development and pathogenesis of disease.
The genesis of disease has been further complexed by involvement of number of 
genes with small effects and above all by population heterogeneity. Accordingly 
variations in genes like Brca1/Brca2 that have been strongly associated with breast 
cancer phenotype present a scattered mutational pattern in different populations. 
This study attempts to analyze the frequently mutated exons of BRCA2 for 
sequence variations in surgically resected breast cancer tissue samples, from a high 
risk ethnic Kashmiri population. PCR followed by direct sequencing revealed 
presence of five variations, with four somatic mutations located on exon 11 and one 
germline variation located in UTR region of exon 2 at contig position 13870572
(rs1799943). All the four somatic mutations comprised of substitutions; two 
representing missense mutations leading to amino-acid substitution at codon 
positions 868 (novel) and 991 whereas other two were silent mutations at codon 
positions 846 and 1131. Codons for amino-acid positions 846 (TCC/TCA) and 868 
(CCT/ACT) were seen to be present in heterozygous state in normal breast tissue 
samples and the heterozygous nature of both the codons was seen to be lost in 
associated tumor samples in 44 out of 50 patients. Incidentally these two mutations 
were always found to be linked. No sequence variations were observed in exons 9, 
18, 20 and 25.
Gap-junction gene Connexin 43, which codes for a 43-kd gap-junction 
protein is a predominantly expressed gap junction protein in normal breast tissue 
and plays an important role in normal mammogenesis, lactogenesis and involution. 
Studies have shown down-regulation of connexin 43 gap-junction protein is 
involved in primary tumor formation as well as metastasis in breast cancer patients
and restoration of gap-junction intercellular communication by up-regulation of 
Abstract
3
connexins has been shown to restore normal phenotypes in vitro and reduce tumor 
growth in vivo. However the molecular mechanisms behind these processes remain 
elusive and a better understanding of the key events is necessary to gain 
information relevant to the designing of anti-cancer treatment models against breast 
cancer. In this study, coding sequence of Connexin 43 was analyzed for 
polymorphic changes to establish its role (if any) in breast cancer in this cohort of 
population. After sequence analysis, none of the screened samples revealed any 
kind of variations in early or advanced stage of the disease. 
The findings from this study add to the body of knowledge about mutation 
prevalence and nature of different breast cancer pre-disposing genes in ethnic 
Kashmiri population, and may inform strategies for genetic cancer risk assessment. 
Our studies also imply that mutational deactivation does not play any role in the 
down regulation of Connexin 43 expression in Kashmiri breast cancer patients. 
Instead, some other regulatory mechanism like hypermethylation or mutation of the 
promoter region of the gene may be involved. Additionally increased understanding 
of breast carcinoma pathways may enhance our ability to device targeted 
approaches to the prevention of disease.
SECTION I
CHAPTER 1
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CHAPTER ONE
INTRODUCTION
Cancer is characterized by abnormal or uncontrolled division of cells, 
dictated by pathological breakdown in the process of cell proliferation (Steward 
& Kliehues, 2003). The cells in our body normally grow and divide in a 
controlled way to keep the body functioning properly. When normal cells grow 
old or get damaged, they die, and new cells take their place. However, this 
process may go wrong to generate new cells even when the body doesn't need 
them, or the old damaged cells may not die as they should. The buildup of extra 
cells often forms a mass of tissue called a lump, growth, or tumor. Thus tumor is 
the outcome of an evolutionary process involving successive generations of cells, 
which progressively advance towards cancerous growth (1). The cancerous cells 
frequently break free from the tumor site and enter the bloodstream, spreading the 
disease to other organs and this process is called metastasis (2).                                                                         
Cancer can develop from almost any type of cell in the body. So more 
than one type of cancer can develop in any one part of the body. Over all there 
are more than 200 types of cancers which develop in 60 different organs of the 
body. Accordingly, the cancers have been grouped into broader categories which 
include Carcinoma (cancer that begins in the skin or in tissues that line or cover 
internal organs), Sarcoma (cancer that begins in bone, cartilage, fat, muscle, 
blood vessels, or other connective or supportive tissue), Leukemia (cancer that 
starts in blood-forming tissue such as the bone marrow and causes large numbers 
of abnormal blood cells to be produced and enter the blood), Lymphoma and 
myeloma (cancers that begin in the cells of the immune system), Central nervous 
system cancers (cancers that begin in the tissues of the brain and spinal cord).                                                                                                                   
About 7.6 million people died of cancer in the year 2007 accounting for 
about 13% deaths the world over. Seventy percent of the total cancer related 
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mortality was faced by low and middle income countries. The global burden of 
cancer continues to rise with cases projected to jump from 12 million to 27 
million and cancer related deaths projected to increase from 7.6 million to 17.5 
million between 2007-2050 (3).
The most common types of cancers with highest rate of mortality are the 
cancers of lung, stomach, liver, colorectal and eosophagus among men and the 
breast, lung, stomach, colorectal and cervical cancers among women. Breast 
cancer, one of the common malignancies affecting women worldwide (Parkin,
2004), account for 25% of all new cases of cancer. However, it ranks as the fifth 
most common cause of death, because of the relatively more favorable prognosis 
(mortality to incidence ratio, 0.35) making it the most prevalent cancer in the 
world today. Breast cancer incidence rate varies widely worldwide (Parkin et al.,
2001) primarily due to range of socio-economic, reproductive, hormonal, 
nutritional and genetic factors (Mcpherson et al., 2000). People in less-developed 
countries surprisingly report low incidence rate than in developed countries.
More than half of the cases are reported from countries like North America and 
Europe (Parkin et al., 2001) whereas South-east Asia contributes over 1/5th of the 
worldwide prevalence of breast cancer.
The wide differences in global incidence rates and resources have led to 
diverse approaches to breast cancer control. In the West, high rates and abundant 
resources have resulted in intense laboratory and clinical research as well as 
aggressive screening programs and abundant treatment trials. In poor-resource
countries with low rates, the ability and incentive to mount large efforts to 
address breast cancer have been lacking. However, the perspective on breast 
cancer control in lower income countries is changing because of the clear trend of 
steeply increasing incidence largely affecting countries with historically low rates 
of breast cancer (Parkin et al., 2001). In Asia; Japan, Singapore, and Korea have 
reported doubled or tripled incidence over the past 40 years and China’s urban 
registries have documented a 50% increase in the years between 1972 and 1994
(Jin et al., 1999). 
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In India, Breast cancer is the second most common cancer among women 
(19%) after cervical cancer (30%), however in the metropolitan cities like Delhi 
and Mumbai, breast cancer has overtaken cervical cancer in frequency (ICMR, 
2001). An average of 80,000 women are diagnosed with carcinoma of the breast, 
and 40,000 die of the disease every year in India (ICMR, 2001). In India, the
major burden of breast cancer is due to early onset breast cancer cases while it is 
mainly a postmenopausal disease in western population. Therefore, although the 
incidence of breast cancer is relatively very high in the west (90.7 versus 23.5),
there is not much difference in the incidence of early onset breast cancer cases 
which varies between 12.33 cases per 100,000 women (Parkin & Iskovich, 1997). 
Kashmir valley (India) which is located at an altitude of 1800-2400 m
from the sea level and borders the low-incidence country and the high-incidence 
area of Pakistan, is distinct from other areas in terms of its unique geographical 
locale, intra-community marriages, tradition, culture, food habits and ethnicity.
Over the past few years, the valley has witnessed a tremendous increase in the 
incidence of breast cancer in its unexplored ethnic population. However, we don’t 
have much and recent population based data available from the valley. Hence in 
this study, we have attempted to examine the epidemiological distribution of 
different cancer types in Kashmir with special emphasis on breast cancer. This is 
the first kind of study which represents the trend in cancer pattern throughout the 
valley. 
CHAPTER 2
REVIEW OF 
LITERATURE
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CHAPTER TWO
REVIEW OF LITERATURE
2.1  DEFINING CANCER
Cancer is a term used for a group of diseases that cause cells in the body
to change and grow out of control. In normal situations, the cells in our body 
grow and divide in a controlled way to produce more cells as they are needed to 
keep the body healthy. However, sometimes the genetic material (DNA) of a cell 
can become damaged or changed, producing mutations that affect normal cell 
growth and division. When this happens cells do not die when they need to and 
the new cells form when they are not required in the body resulting in lump or 
mass called a tumor (1).
Cancers are capable of spreading throughout the body by two 
mechanisms: invasion and metastasis. Invasion refers to the direct migration and 
penetration by cancer cells into neighboring tissues. Metastasis refers to the 
ability of cancer cells to penetrate into lymphatic and blood vessels, circulate 
through the bloodstream, and then invade normal tissues elsewhere in the body. 
Depending on whether or not they can spread by invasion and metastasis, tumors 
are classified as being either benign or malignant. Benign tumors are tumors that 
cannot spread by invasion or metastasis; hence, they only grow locally. 
Malignant tumors are tumors that are capable of spreading by invasion and 
metastasis (2).
There are more than 200 different types of cancers which may arise in 
over 60 different organs in the body. Each organ is made up of several different 
types of cells. For example, there is usually a surface covering of skin or 
epithelial tissue. Underneath that, there is often a layer of muscle tissue and so 
on. Each type of tissue is made up of specific types of cells. Cancer can develop 
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from almost any cell type in the body, although one type of cancer will be much 
more common than the others. Broadly, cancer can be grouped into following 
categories:
 Carcinoma - cancer that begins in the skin or in tissues that line or cover 
internal organs. 
 Sarcoma - cancer that begins in bone, cartilage, fat, muscle, blood 
vessels, or other connective or supportive tissue. 
 Leukemia - cancer that starts in blood-forming tissue such as the bone 
marrow and causes large numbers of abnormal blood cells to be produced 
and enter the blood.
 Lymphoma and myeloma - cancers that begin in the cells of the immune 
system.
 Central nervous system cancers - cancers that begin in the tissues of the 
brain and spinal cord.
Cancer is caused by both external factors (tobacco, infectious organisms, 
chemicals, and radiation) and internal factors (inherited mutations, hormones, 
immune conditions, and mutations that occur from metabolism). These causal 
factors may act together or in sequence to initiate or promote carcinogenesis. Ten 
or more years often pass between exposure to external factors and detectable 
cancer. Knowledge about the causes of cancer, and interventions to prevent and 
manage the disease is extensive. Cancer can be reduced and controlled by 
implementing evidence-based strategies for cancer prevention, early detection 
and management. One-third of cancers could be cured if detected early and 
treated adequately, based on the observation that treatment is more effective at 
early stages. In addition, more than 30% of cancers could be prevented simply by 
behavioral changes that include abstinence from using tobacco, use of healthy 
diet, maintaining a healthy weight, being physically active and preventing 
infections that may cause cancer (Danaei et al., 2005).
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2.2  OCCURRENCE
In 2007, 7.6 million people died of cancer, around 13% of all deaths 
worldwide, with more than 70% of deaths occurring in low and middle income 
countries. The global burden of cancer continues to rise wherein the new global 
cases are estimated to jump from 12 million to 27 million and global cancer 
deaths are projected to increase from 7.6 million to 17.5 million deaths in 2007-
2050 (3). Lung cancer is the main cancer in the world today, whether considered 
in terms of numbers of cases (1.35 million) or deaths (1.18 million), because of 
the high case fatality (ratio of mortality to incidence, 0.87). Breast cancer, the 
second most common cancer overall (1.15 million new cases), ranks less highly 
(fifth) as a cause of death because of the relatively favorable prognosis (mortality 
to incidence ratio, 0.35), and cancers of the stomach (934,000 cases, 700,000 
deaths), liver (626,000 cases, 598,000 deaths), and colon and rectum (1.02 
million cases, 529,000 deaths) rank more highly (Parkin et al., 2002).
2.3  BREAST CANCER INCIDENCE WORLDWIDE
Globally, breast cancer is the second most common tumor in the world 
and represents 9% of global cancer burden (Parkin et al., 2000). It is the most 
frequent cancer of women, account for 25% of all cancers. More than half of the 
cases are in industrialized countries—about 361,000 in Europe (27.3% of cancers 
in women) and 230,000 in North America (31.3%). Incidence rates are high in 
most of the developed areas (except for Japan, where it is third after colorectal 
and stomach cancers), with the highest age-standardized incidence in North 
America (99.4 per 100,000) (Jemal et al., 2004). In part, the high incidence in the 
more affluent world areas is likely because of the presence of screening programs 
that detect early invasive cancers, some of which would otherwise have been 
diagnosed later or not at all (IARC, 2002). The incidence is more modest in 
Eastern Europe, South America, Southern Africa, and Western Asia, but it is still 
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the most common cancer of women in these geographic regions. The rates are 
low (30 per 100,000) in most of Africa (with the exception of South Africa) and 
Asia. The Globocan database indicates that the age-standardized rate (ASR) of 
breast cancer incidence is 66.4 per 100000 in more-developed regions (Europe, 
Australia, New Zealand, North America and Japan) compared with 27.3 per 
100000 in less-developed regions (Africa, Central America, South America, all 
regions of Asia except Japan, the Caribbean, Melanesia, Micronesia and 
Polynesia) (3).
Breast cancer incidence varies widely within regions and countries, likely 
due to differences in racial and ethnic make-up, health resources, and lifestyle 
patterns (Mcpherson et al., 2000; Parkin et al., 2001). Incidence in largely rural 
and black sub-Saharan Africa (16.5 per 100000), for instance, is half that of 
South Africa (33.5 per 100000), which has a higher proportion of urban white 
women (Ferlay et al., 2002). In China, the 1993-1997 incidence of breast cancer 
in urban Shanghai was 27.2 per 100000 compared with 11.2 per 100000 in the 
more rural Qidong country (Chen et al., 2006; Parkin et al., 2005). In Korea there 
was an almost two-fold difference in incidence between Seoul (20.8 per 100000) 
and more rural Kanghwa county (12.7 per 100000) (Parkin et al., 2005).
The wide difference in global incidence rates and resources has led to 
diverse approaches to breast cancer control. In the West, high rates and abundant 
resources have resulted in intense laboratory and clinical research as well as 
aggressive screening programs and abundant treatment trials. In resource-poor 
countries with low rates, the ability and incentive to mount large efforts to 
address breast cancer have been lacking. However, the perspective on breast 
cancer control in lower income countries is changing because of the clear trend of 
steeply increasing incidence largely affecting countries with historically low rates 
of breast cancer (Parkin et al., 1992). In Asia; Japan, Singapore, and Korea have 
reported doubled or tripled incidence over the past 40 years and China’s urban 
registries documented a 50% increase in the years between 1972 and 1994 (Jin et 
al., 1999). India similarly reported increased incidence in urban Bombay 
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(Mumbai) from 1978 to 1997 (20.5 to 31.5 per 100000) (Parkin et al., 2005). In 
Africa, trends in breast cancer incidence are difficult to evaluate, given the 
general lack of large registries and accurate population data. However, local 
registry efforts in Uganda, reported increased incidence from 11.7 in 1960 to 23.4 
in 2002 (Parkin et al., 2008). Some Latin American countries have also reported 
increasing incidence: in Cali, Colombia rates increased from 32.2 in 1983 to 44.4 
in 1997. However, in Costa Rica, which has one of Latin America’s only national 
registries, the rate has remained fairly constant at around 30 per 100000 (Parkin 
et al., 2005).
2.4 BREAST CANCER INCIDENCE IN INDIA
Breast cancer shows uneven geographical distribution in its occurrence 
reflecting the influence of local environmental conditions, lifestyle, 
hormonal/reproductive pattern and genetic predisposition in the development of 
the disease (McPherson et al., 2000; Parkin et al., 2001). People in less-developed 
countries report low incidence rate than in developed countries. The high 
incidence areas include North America and European countries (Parkin et al., 
2001). South-East Asia contributes over 1/5th of the worldwide prevalence of 
breast cancer with Pakistan having highest incidence among Asian population 
after Israel (Bhurgri et al., 2000). Breast cancer is the second most common 
cancer among Indian women (19%) after cervical cancer (30%), however in the 
metropolitan cities like Delhi and Mumbai, breast cancer has overtaken cervical 
cancer in frequency (ICMR, 2001). In India an average of 1,15000 women are 
diagnosed with carcinoma of the breast, and 50,000 women die of the disease 
every year (5). Interestingly, there is also a significant difference in the incidence 
of breast cancer between urban and rural population of India and it also varies 
among various religious groups, the highest (1.5–2.1 times) being in Parsi 
population as compared to either Hindu, Muslim or Christian population 
(Jussawalla & Jain, 1977). Regionally, incidence rates ranges from 18.8 per 105 
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in Trivandrum to 28.2 per 105 in Mumbai. These differences in breast cancer 
incidence clearly reflect the diversity of ethnic and religious groups in India.
Kashmir valley located at an altitude of 2000m above sea level is bordering the 
low incidence country India and the high-incidence area of Pakistan. Breast 
cancer in Kashmiri women is the 2nd common cancer after oesophageal cancer.
2.5  MORTALITY FROM BREAST CANCER
Although breast cancer is the second common cancer in the world, but it 
ranks  as the fifth cause of death from cancer overall, because of its good 
prognosis which is illustrated by the survival rates, the average in developed 
countries is 73% and 57% in developing countries. Because of its high incidence 
and relatively good prognosis, breast cancer is the most prevalent cancer in the 
world today. There are an estimated 4.4 million women alive who have had 
breast cancer diagnosed within the last 5 years (compared with just 1.4 million 
survivors—male or female—from lung cancer). The worldwide ASR for 
mortality from breast cancer between 1993 to 2001 was 13.2 per 100000, ranging 
from 8.8 in Asia to 19.7 in Europe (Kamangar et al., 2006). The rate in ‘more 
developed’ countries was 18.1 compared with 10.4 in ‘less developed’ countries. 
The higher overall mortality rate in high resource countries reflects the high 
incidence of the disease in many of those countries. However, the burden of 
deaths due to breast cancer in lower resource countries is disproportionately high. 
Although the ratio of the mortality rate to incidence rate (MR:IR) world-wide is 
0.35, it varies widely and ranges from a high of 0.69 in Africa to a low of 0.19 in 
North America. 
High mortality rates in low resource countries are primarily due to late-
stage disease presentation. For example, the high MR:IR ratio in Africa to a large 
degree reflects the high proportion of women in many African countries who 
present with late-stage cancer. In sub-Saharan African countries, small studies 
indicate that up to 90% of women present with stage III or VI disease, many with 
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large tumors (median of 10 cm) and clinically apparent lymph node metastasis 
(Fregene & Newman, 2005; Parkin et al., 2008). These late-stage tumors cannot 
be treated successfully in the most optimal settings. Inadequate health care 
systems also contribute to high mortality rates. There are no examples of 
universal breast cancer screening in low resource countries that could down-stage 
breast cancer diagnoses. In addition, there are typically only a few hospitals that 
can administer radiotherapy and chemotherapy and very few trained oncologists 
(Nigeria, for instance, has approximately 100 oncologists for a population of 140 
million) (Igene 2008). National expenditure on health care overall inversely 
correlates with mortality from breast cancer, but there are exceptions (Igene,
2008). In Cuba, health expenditure is only moderate but mortality remains lower 
than that in the US (2004 ASR 14.2 and 15.6 respectively) where per capita 
health care spending is the highest in the world (Igene, 2008). Sweden also 
spends less on health care than the US, but maintains a similar mortality rate 
(ASR 15.6). Given these kinds of exceptions, it is important that not only the total 
health expenditure but the distribution of that expenditure into effective private or 
public systems be considered when judging approaches to reducing the burden of 
breast cancer. 
2.6 APPROACHES TO REDUCING BREAST CANCER INCIDENCE 
AND MORTALITY 
Although progress in slowing the rate of increasing incidence would be 
desirable, the increasing prevalence of lifestyle habits that accompany improving 
economic conditions –delayed childbearing, lower parity, reduced breast-feeding, 
and a sedentary workplace– are expected to continue to drive up breast cancer 
incidence rates in lower and middle resource countries in the coming decades. 
The most important task will be to alter the trend of increasing mortality that will 
accompany the increasing rate. The strategies that have been most effective in 
predominantly Caucasian, affluent populations have been early detection through 
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mammography, targeted hormonal and anti-HER2 therapies, and improvements 
in chemotherapy. The common presentation of breast cancer at advanced stage in 
lower income countries is undoubtedly one of the main reasons for high mortality 
rates; metastatic disease is not treated successfully in countries with the highest 
resources. Down staging of breast cancer by early detection is seen as one of the 
most promising long-term strategies for preventing disease-related deaths but it is 
difficult for many countries to make the economic investment required to carry 
out broad screening programs. The lowest cost screening modality, breast self 
exam (BSE), can find individual tumors and increase awareness and acceptance 
of breast health in the population but does not appear to lower mortality from the 
disease (Thomas et al., 2002). Clinical breast exam (CBE) can improve detection 
of early stage cancers and clinical follow-up within the health care system
(Okonkwo et al., 2008) and efforts are being made in many countries to train 
medical personnel to conduct high quality CBE. Full-scale mammography 
screening has been successful in reducing mortality in developed countries
(Cronin et al., 2006), but this requires considerable human, health system and 
technical resources. It is likely that a combined introduction of BSE, CBE and 
mammographic screening as is possible for an increasing proportion of the 
population, will be the most feasible course of action for lower resource 
countries. The multinational groups involved in the Breast Health Global 
Initiative have incorporated economic and cultural information into guidelines to 
help plan just such country-specific breast cancer early detection strategies in 
lower-resource countries with different racial, ethnic, and cultural makeup
(Anderson, 2008).
It is clear that breast cancer will be an increasing burden in many 
countries and there will have to be a redirection of health resources to diagnose, 
treat and monitor the growing numbers of women who are affected by the 
disease. This will take political will, reliable data and cancer registries, public and 
medical community awareness, and partnerships between advocates, government, 
foundations and NGOs, and biotechnology companies. These partnerships can 
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provide the incentives and the means to make crucial advances in lowering the 
unacceptable burden of mortality in lower resource countries.
CHAPTER 3
MATERIALS AND 
METHODS
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CHAPTER THREE
MATERIALS AND METHODS
2.1  DATA SOURCE
  This study is based on the records of cancer patients registered in the 
Department of Radiation Oncology, Sheri-Kashmir Institute of Medical Sciences, 
Srinagar, and Department of Radiation Oncology, SMHS, Srinagar. All the 
patients who are diagnosed of cancer and come to these hospitals for further 
treatment are registered in the registration section of these departments. These are 
leading medical centers in the valley and draw almost all of cancer patients from 
all over Kashmir for treatment. Although some of the patients report to district 
hospitals, but they are also finally referred to these specialist hospitals for 
treatment.
   The patient’s records were screened for information on the nature and 
distribution of all forms of cancer reported to the department between January 
2002 and December 2006. Records of patients from outside the valley of Kashmir
were excluded from the study. The mean annual frequencies of all cancer types 
were worked out and tabulated by sex. The main forms of cancer were identified 
separately for men and women as well as collectively.
2.2  STATISTICAL METHODS 
   The results are presented as incidence rates of cases by age, sex, site, crude 
rate, age specific incidence rates and age standardized incidence rates. The data 
on annual population of Kashmir region by 5-year age group and sex for the 
period 2002–2006 was provided by Population Research Centre, University of 
Kashmir. The annual populations during the study period of 2002–2006 were 
Materials & Methods
17
cumulated for calculation of measures of incidence. All incidence rates were 
expressed as average annual ones per 100,000 persons. The total population 
during 2002-06 was 28672263. The sex ratio in Kashmir is 918 females per 1,000 
males. Table 3.1 gives the population at risk by sex and 5 year age groups.
Age group (in 
years)
Males Females
<1 270362 245739
1 to 4 976306 873740
5 to 9 1607149 1447131
10 to 14 1635688 1625975
15-19 1785887 1544061
20-24 1515527 1421192
25-29 1365326 1325627
30-34 1034884 957018
35-39 974804 902409
40-44 751004 697626
45-49 732980 547452
50-54 539221 615713
55-59 479140 479192
60-64 495663 354956
65-69 300401 245739
70-74 270361 163826
75-79 120161 95565
80+ 165220 109217
Total 15020084 13652178
Table 3.1: Population at risk by five year age group and sex, Kashmir, 2002-06.
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CHAPTER FOUR
RESULTS
During the period under review that is from 2002 to 2006, 6943 new cases 
were registered in Kashmir valley, which gives an average of 1389 new cases per 
annum. Of these new cases, 4345 were males and 2598 were females indicating a 
male female ratio of 1.67: 1.0. The number of cases by site, age group, 
percentage, crude rates and Age-standardized rates for males and females are 
given in Tables 4.1a and 4.1b and Age-specific incidence rates are given in 
Tables 4.2a and 4.2b respectively. 
In males, Oesophageal cancer (Oesophagus and GE junction) was the 
most commonly reported malignancy (30.9% of all cases, ASR 11.2) followed by 
lung (17.9%% of all cases, ASR 6.5), brain (7.0% of all cases, ASR 2.2), head 
and neck (6.4% of all cases, ASR 2.2), skin (5.4% of all cases, ASR 1.9) and 
stomach (5.2% of all cases, ASR 1.8). The crude rate for all sites combined was 
29 per 100,000 and 34.9 ASR per 100,000 for males.
Oesophageal cancer (32.8%, ASR 8.3) was the most frequently reported 
malignancy in females followed by breast (22.8%, ASR 5.2), skin (6.2%, ASR 
1.6), rectum (4.2% ASR 0.95), brain (4.2%, ASR 0.9) and lung (4.1% ASR 1.1). 
The crude and age adjusted (world population) incidence rates for females were 
19.2 per 100,000 and 24.8 per 100,000 respectively. Oesophageal and lung 
cancers alone contributes about 45% of total cases in males whereas in females 
esophageal and breast cancers contribute more than 50% of the cases. Overall in 
both the sexes, oesophagus is the leading cancer site followed by breast and lung 
in the valley. Our results have shown that breast cancer occurs with highest 
incidence in the age group of 20-50 whereas above 50, Breast cancer is the 2nd
leading cancer after oesophageal cancer. In males, the occurrence of Breast 
cancer is very less in all age groups.
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In cancer types common to both the sexes, the proportion in the men 
exceeds that in women in almost all types of cancer Tobacco-related cancers, i.e., 
Head & Neck (oral cavity, pharynx and larynx) and lung constituted 24% of the 
total male cancers, while in females they accounted for only 7.6% of the cases. 
Our results clearly indicate that cancer occurs mostly at older ages as only 3.4% 
of the total number of cancer cases registered, were falling in the age group of 
less than 20 years, although this age group accounts for a good percentage of the 
total population. The overall percentage of new cancer cases was more in the age 
group of 50-70 years as compared to other age groups in both sexes. In male 
children, the most prominent cancer was brain followed by lymphomas and bone 
& soft tissue; whereas in female children, bone & soft tissue is the leading site 
followed by brain and eye cancers.
Figure 4.1 shows the comparison of total number of incident cases of 
cancer (from year 2002-2006) at different cancer sites in males & females. Figure 
4.2 show the age-specific incidence rate curves for all sites in males and females. 
In males there is a steady increase up to 50 years age group and then sharp 
increase in the age group of 50-70 which is followed by progressive decrease in 
the older age groups (70+). Whereas in females, the rates increase steadily up to 
the age of 70 years and then falls in the older age groups. Figure 4.3a shows the 
age-specific curves for esophagus, lung, brain, head and neck, stomach and skin 
in males and Figure 4.3b the equivalent curves for oesophagus, breast, skin, 
rectum, brain and lungs in females.
    Tables 4.3a and 4.3b compare the age-standardized incidence rates for 
common sites in Kashmir with the registries reported from India in males and 
females respectively (Curado et al., 2007; Manoharan et al., 2009, 2010; Sen et 
al., 2002). Among males as well as females, Kashmir reports the highest 
incidence of oesophageal cancer cases in India. Compared to other Indian cancer 
registries, the incidence of cervical cancer in females is lower in Kashmir. 
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Site 0-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+ Total %age
Distribution
Crude 
rate
ASR
Oesophagus x x 32 126 302 448 199 44 7 1158 26.7 7.7 9.7
Lung x 4 15 123 210 267 127 29 2 777 17.9 5.2 6.5
GE Junction x x 4 16 50 71 38 3 x 182 4.2 1.2 1.5
Skin x 4 7 29 61 71 39 20 2 233 5.4 1.6 1.9
Prostrate x x X 2 5 27 19 6 1 60 1.38 0.4 0.5
Rectum 1 31 20 31 42 57 12 3 x 197 4.5 1.3 1.5
Stomach x 5 17 35 69 67 25 7 x 225 5.2 1.5 1.8
Colon x 6 14 17 31 29 16 x x 113 2.6 0.8 0.9
Testis 4 7 22 27 10 6 5 x x 81 1.9 0.5 0.6
Urinary Bladder x x 3 9 12 21 11 3 2 61 1.4 0.4 0.5
Thyroid 1 2 5 7 11 19 2 x x 47 1.1 0.3 0.4
Bone & Soft tissue 18 16 16 13 13 9 4 x x 89 2.0 0.6 0.6
Eye 10 3 3 x 7 3 x x x 26 0.6 0.2 0.2
Brain 53 49 57 55 51 34 6 x x 305 7.0 2.0 2.2
Breast x x 5 9 13 11 7 4 x 49 1.1 0.3 0.4
Multiple myeloma x x 5 7 20 21 4 x x 57 1.3 0.4 0.5
Gall bladder 2 1 1 4 12 3 x x x 23 0.53 0.2 0.2
Renal 7 2 X 12 14 13 4 x x 52 1.2 0.4 0.5
Muscle 5 1 5 9 7 2 3 x x 32 0.74 0.2 0.2
Head & Neck 10 6 29 57 57 69 25 15 9 277 6.4 1.8 2.2
Lymphomas 49 42 30 49 27 36 7 4 x 244 5.6 1.6 1.7
Others & 
Unspecified
2 4 6 14 21 7 3 x x 54 1.2 0.4 0.4
Total 162 183 296 651 1045 1291 556 138 23 4345 100 29 34.9
                              
Table 4.1a: Incidence Cases, Rates by site and age group, relative frequencies (%), Average 
annual Crude Incidence rates (CR) and Age-Standardized Incidence rates 
(ASR) in men in Kashmir, 2002-2006.
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Cancer Type 0-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+ Total %age
Distribution
Crude 
rate
ASR
Oesophagus 1 6 33 141 273 223 97 25 2 801 30.8 5.9 7.8
Breast x 22 125 192 152 73 25 4 x 593 22.8 4.3 5.2
Lung x x 7 22 24 33 15 5 x 106 4.1 0.8 1.1
Skin x 8 7 23 44 53 17 6 2 160 6.2 1.2 1.6
GE Junction 1 3 4 9 18 9 7 1 x 52 2.0 0.4 0.5
Rectum x 20 19 27 24 17 3 x x 110 4.2 0.8 0.95
Stomach x x 6 5 22 14 11 3 x 61 2.3 0.5 1.0
Colon 1 4 7 13 17 16 3 x x 61 2.3 0.5 0.6
Cervix x x 12 26 15 33 2 6 x 94 3.6 0.7 0.9
Urinary Bladder x x 3 4 8 5 x x x 20 0.8 0.2 0.2
Thyroid 4 4 8 5 1 3 4 x x 29 1.1 0.2 0.2
bone & Soft tissue 16 12 6 6 8 5 3 x x 56 2.2 0.4 0.5
Eye 11 x x 2 3 x x x x 16 0.6 0.1 0.1
Brain 13 20 24 11 28 9 3 x x 108 4.2 0.8 0.9
Multiple Myeloma x x 3 7 11 19 x x x 40 1.5 0.3 0.4
Gall Bladder 1 1 4 14 14 4 2 x x 40 1.5 0.3 0.5
Renal 4 1 3 4 11 8 2 x x 33 1.3 0.2 0.5
Muscle 8 x 2 3 5 2 x x x 20 0.8 0.1 0.2
Head & Neck 5 4 4 21 22 25 6 3 x 90 3.5 0.7 0.8
Lymphomas 6 19 12 9 10 9 3 x x 68 2.6 0.5 0.6
Others & 
unspecified
2 5 6 8 12 4 2 1 x 40 1.5 0.3 0.3
Total 73 129 295 552 722 564 205 54 4 2598 100 19.2 24.8
Table 4.1b: Incidence Cases, Rates by site and age group, relative frequencies (%), Average 
annual Crude Incidence rates (CR) and Age-Standardized Incidence rates 
(ASR) in women in Kashmir, 2002-2006.
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Table 4.2a: Age-Specific Incidence rates (ASR) by site and age group in men in Kashmir,
2002-2006.
Site 0-19 20-29 30-39 40-49 50-59 60-69 70-79 80+
Oesophagus x x 1.59 8.49 29.65 56.27 50.95 30.86
Lung x 0.13 0.75 8.28 20.62 33.54 32.52 18.76
GE 
Junction
x x 0.2 1.1 4.9 8.92 9.73 1.82
Skin x 0.14 0.35 1.95 6 8.92 9.98 13.3
Prostrate x x x 0.13 0.49 3.4 4.86 4.23
Rectum 0.016 1.08 0.99 2.08 4.12 7.16 3.07 1.81
Stomach x 0.17 0.85 2.35 6.77 8.41 6.4 4.23
Colon x 0.2 0.69 1.15 3 3.64 4.1 x
Testis 0.063 0.24 1.09 1.81 0.98 0.75 1.28 x
Urinary 
Bladder
x x 0.15 0.6 1.18 2.63 2.81 3
Thyroid 0.016 0.069 0.25 0.47 1.08 2.4 0.51 x
Bone & Soft 
tissue
0.29 0.21 0.79 0.88 1.27 1.13 1.02 x
Eye 0.16 0.1 0.15 x 0.69 0.38 x x
Brain 0.84 1.7 2.83 3.7 5 4.27 1.53 x
Breast x x 0.25 0.6 1.27 1.38 1.8 2.4
Multiple 
myeloma
x x 0.25 0.47 1.96 2.63 1.02 x
Gall 
bladder
0.032 0.035 0.049 0.27 1.18 0.38 x x
Renal 0.11 0.07 x 0.8 1.37 1.63 1.02 x
Muscle 0.08 0.035 0.25 0.6 0.68 0.25 0.77 x
Head & 
Neck
0.16 0.2 1.44 3.84 5.59 8.66 6.4 14.5
Lymphomas 0.78 1.45 1.5 3.3 2.65 4.52 1.78 2.4
Others & 
Unspecified
0.03 0.14 0.29 0.94 2.1 0.88 0.77 x
Total 2.6 5.97 14.7 43.8 102.6 162.2 142.3 97.3
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Table 4.2b: Age-Specific Incidence rates (ASR) by site and age group in women in Kashmir,           
2002-2006.
Cancer 
Type
0-19 20-29 30-39 40-49 50-59 60-69 70-79 80+
Breast x 0.8 6.7 15.4 13.9 12.2 9.64 3.66
Lung x x 0.38 1.77 2.2 5.5 5.8 4.6
Skin x 0.3 0.38 1.8 4 8.8 6.6 7.3
GE 
Junction
0.017 0.11 0.22 0.72 1.64 1.5 2.7 0.92
Rectum x 0.73 1 2.2 2.2 2.83 1.6 x
Stomach x x 0.32 0.4 2 2.33 4.2 2.75
Colon 0.017 0.15 0.38 1 1.55 2.66 1.6 x
Cervix x x 0.65 2 1.37 5.5 0.77 5.5
Urinary 
Bladder
x x 0.16 0.32 0.73 0.83 x x
Thyroid 0.07 0.15 0.43 0.4 0.09 0.5 1.54 x
bone 0.28 0.44 0.32 0.48 0.73 0.83 1.6 x
Eye 0.19 x x 0.16 0.27 x x x
Brain 0.23 0.73 1.3 0.88 2.56 1.5 1.6 x
Multiple 
Myeloma
x x 0.16 0.56 1 3.1 x x
Gall 
Bladder
0.017 1 0.22 1.1 1.3 0.67 0.77 x
Renal 0.07 1 0.16 0.32 1 1.33 0.77 x
Muscle 0.14 x 0.11 0.24 0.46 0.33 x x
Head & 
Neck
0.09 0.036 0.22 1.7 2 4.2 2.3 2.75
Lymphomas 0.1 0.69 0.65 0.72 0.91 1.5 1.6 x
Others & 
unspecified
0.035 0.18 0.32 0.64 1.1 0.67 0.77 0.92
Total 1.27 6.54 15.9 44.1 65.9 93.9 81.3 53.1
Results
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Site Kashmir Chennai# Kolkata** Rural 
Delhi##
Urban 
Delhi*
Mumbai# Poona# Nagpur# Trivandrum# Karunag
apally#
Oesophagus 11.2 9.1 4.5 2.7 4.9 6.7 6.1 8.7 3.5 8.3
Lung 6.5 10.8 18.7 13.8 10.7 9.7 6.2 7.5 9.9 21.3
Brain 2.2 3 2.0 1.7 4 3.7 3.6 3.0 2.9 3.7
Head & Neck 2.2 21.9 20.3 16 25 22.2 19.5 23.5 23.3 22.3
*Data from Curado et al, 2007; **Sen et al., 2002; ## Manoharan et al., 2009; * Manoharan et al., 2010
Table 4.3a: Age Standardized Incidence Rates (per 100,000) for Common Sites in Kashmir 
and other Indian Registries- Males.
       Site Kashmir Chennai# Kolkata** Rural 
Delhi##
Urban 
Delhi*
Mumbai# Poona# Nagpur# Trivandrum# Karunag
apally#
Oesophagus 8.3 5.4 3.5 2.6 3.1 3.4 5.0 5.7 0.9 2.0
Breast 5.2 26.5 25.1 7.8 30.0 26.9 24.4 27.4 24.6 16.0
Rectum 0.95 1.4 2.0 0.6 1.8 1.4 2.4 1.8 2.2 1.4
Brain 0.9 2.1 1.5 1.5 2.4 2.8 1.9 2.6 2.2 1.9
Lung 1.1 2.6 4.9 1.0 3.4 3.1 3.0 2.4 1.7 2.3
Cervix 0.9 28.0 9.4 10.3 17.5 14.5 17.3 18.4 9.4 10.6
*Data from Curado et al, 2007; **Sen et al., 2002; ## Manoharan et al., 2009; * Manoharan et al., 2010
Table 4.3b: Age Standardized Incidence Rates (per 100,000) for Common Sites in Kashmir 
and other Indian Registries- Females.
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Fig 4.1: Comparison of total number of incident cases of cancer (from year 2002-2006) at 
different cancer sites in males & females.
Figure 4.2: Age-specific Incidence Rate Curves.
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Figure 4.3a: Age-specific Incidence Rate Curves for Oesophagus, Lung, Brain, Head & 
Neck, Skin and Stomach cancers in Males.
    
Figure 4.3b: Age-specific Incidence Rate Curves for Oesophagus, Breast, Skin, Rectum, 
Brain and Lung cancers in Females.
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Figure 4.4a: Comparison of new incident cases at different sites in males & females (Year 
2002).
Figure 4.4b: Comparison of new incident cases at different sites in males & females (Year 
2003).
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Figure 4.4c: Comparison of new incident cases at different sites in males & females (Year 
2004).
Figure 4.4d: Comparison of new incident cases at different sites in males & females (Year 
2005).
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Figure 4.4e: Comparison of new incident cases at different sites in males & females (Year 
2006).
CHAPTER 5
DISCUSSION
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CHAPTER FIVE
DISCUSSION
This study on the incidence pattern of different types of cancer was 
conducted on an ethnic population and almost all of the patients report either to 
the SMHS Hospital or Sher-i-Kashmir Institute of Medical Sciences, except the
few numbers that go outside valley for treatment. The public acceptance of 
allopathic treatment is high and no alternative therapies such as homeopathy and 
ayurvedic exist in the valley. A well-flourished network of investigative 
laboratories at district and sub-district level is present and a good referral system 
between these health centers and the specialist institutions primarily involved in 
treating this disorder exists.
In Kashmir, oesophageal cancer is the most predominant cancer present in 
males as well as females. This cancer by far exceeds the frequency of other 
cancers in both the sexes contributing about 30% to the total number of cancer 
cases in Kashmir. The preponderance of oesophageal cancer can be ascribed to 
the life style and local dietary habits among Kashmiris as various epidemiological 
studies in regions of the world with high incidences of oesophageal cancer have
substantiated the important role of these two in the incidence pattern of 
oesophago-gastric cancer (Kmet & Mahboubi, 1972; Malhotra, 1967; Siddiqi & 
Preussmann, 1989; Warwick, 1973; Yang, 1980). The most important specific 
food habit in Kashmir is the frequent consumption of hot salt tea by local 
inhabitants, more so during the winter months when the temperature falls to 
subzero levels. The salt tea is prepared traditionally in a specially designed 
copper vessel called a 'samawar'. The samawar consists of a central smoke stack 
with a perforated base (fed with live charcoal) mounted on a stand and a 
surrounding jacket for boiling the salt tea infusion. The tea is prepared by 
brewing green tea leaves (not grown in Kashmir) in sodium bicarbonate until a 
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thick red brown-colored extract is obtained. The extract is diluted with water and 
then milk and salt are added. The tea is customarily served boiling hot and is 
consumed with or without snacks. The components of salted tea like sodium 
bicarbonate and common salt, a well known irritant of gastric epithelium (Correa,
1987) are believed to be the chief suspects causing oesophageal cancer.                                                 
Another specific dietary habit which is very particular to Kashmiri 
population is the practice of drying raw food stuffs in open sun and this dried 
food is stored and later on consumed in the winter months (Siddiqi & 
Preussmann, 1989). Studies have shown that these foods contain significant 
amounts of N-nitroso compounds (Tricker et al., 1988). In addition, other 
Kashmiri food items contributing substantial amount of N-nitroso compounds 
include salt tea, dried fish, vegetables especially Brassica olerecea (haak), red 
chillies, and spice cake (wur) (Siddiqui et al., 1988, 1990). In addition, salt tea 
showed the formation of high amounts of N-nitrosopipe-colic acid with several 
unidentified non-volatile N-nitroso compounds on nitrosation of tea extracts 
under conditions simulating the fasting human stomach (Siddiqui et al., 1988(2)).                                                                                                                
Lung cancer ranks next to esophageal cancer in males in the valley. Its 
association with smoking has been substantiated by innumerable studies, some of 
which have also established a dose response relationship, in terms of the number 
of cigarettes smoked per day and the risk of developing lung cancer (Arya et al., 
1991; Charles, 1991; Peter, 1993).
Case control studies conducted in places like Kerala (Sankarnarayanan et 
al., 1994), Bhopal (Dikshit & Kanhere, 2000) and Chandigarh (Gupta et al.,
2001) reported a high risk of lung cancer among bidi and cigarette smokers 
showing a direct link between the two. A case control study from Chandigarh 
also suggested that environmental smoke exposure may be a strong risk factor for 
lung cancer in India (Rapiti et al., 1999). Smoking is popular throughout India, 
where besides cigarettes, pipes and cigars; it takes various indigenous forms such 
as bidi, hookah, and chilam. In Kashmir, besides cigarette smoking, which is 
mainly practised in urban and semi-urban localities, the most popular form is 
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hubble bubble (hukkah) whereby the smoke is inhaled after it is cooled and 
filtered by passing through water placed in an earthen container and is largely 
responsible for passive smoking of other family members, especially during 
winter months. Smoking in the valley is a male pastime; the women do not 
generally smoke. That is the why we can clearly see the preponderance of lung 
cancer in males as compared to the females. The relatively higher prevalence of 
oesophageal cancer in the men may also result from the additional influence of 
smoking. While in developed countries, such as the USA, lung cancer is a leading 
cause of death in both sexes (Jemal et al., 2002), it is mostly a disease of men in 
India, as is also shown in this study. 
Brain cancer is the third common site of cancer in males in Kashmir 
accounting for 7% of all cancer cases. This cancer was found to be more common 
in the male children accounting for 17.4% of total cases in the age group of 0-20 
and more than 50% of the cases in the age-group of 0-40 years.  
Breast cancer, the most frequent cancer of women in the world is the 
second leading site of cancer in females in Kashmir. It constituted about 23% of 
all cancers in women whereas in males, it is hardly found to occur and just 
contributes 1% of all cancers. Overall in both males and females, it is the second 
most common cancer present in the valley. On comparing the incident cases of 
breast cancer in different age groups, it is clearly seen that the early onset cases 
(0-40 age group) contribute about 25% of the total number of breast cancer cases 
in females. Although the disease is mainly postmenopausal in western 
population, but the picture in Kashmir is no different than the rest of the country 
where the burden of breast cancer due to early onset cases is increasing at an 
alarming rate. Though the etiology of breast cancer in India has not been widely
studied, case-control studies from Mumbai (Rao et al., 1994) and Chennai 
(Gajalakshmi & Shanta, 1991) have identified null parity, early menarche, late 
age at marriage and late age at pregnancy as risk factors.
The higher frequency of skin cancer in men as well as women is perhaps 
caused by the greater exposure to the sun that they receive especially while 
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farming. Additionally, studies have shown that the use of firepot, (kangri) an 
ingenious mode of providing warmth during extreme cold conditions in the valley 
also contribute towards skin cancer in the valley (Wani, 2010).
Interestingly, our resulting are showing a different pattern of cancer in 
Kashmiri women population. In our women population, the frequency of cervical 
cancer is very low which is quite contrary to the pattern in rest of the country 
where cervical cancer is the second leading cancer in females after breast cancer
(ICMR, 2001). This change in pattern and the lower rate of cervical cancer which 
is just 3.6% can be attributed to the practice of universal circumcision, prevalent 
in the majority community of Kashmir. 
The sex differentiation was exceedingly significant in breast and tobacco 
associated cancers. The former was excessively present in females whereas latter 
was present in males. Though, this difference in occurrence of tobacco associated 
cancers can be attributed to smoking habit in men, however  in case of breast 
cancer, its distribution can be attributed to anatomical and physiological 
differences. 
The pattern observed from the analysis of the available data provides 
comprehensive information on cancer occurrence in the valley and these results 
will help to evaluate a cancer control program in this region. In conclusion, our 
study has shown that in Kashmir valley oesophageal cancer is the leading cancer 
in both males as well as females, followed by lung cancer in males and breast 
cancer in females. So, counseling, awareness campaigns, change of dietary habits 
and life style are the primary measures to be taken to prevent this oesophageal 
cancer epidemic in the valley. Additionally, the primary prevention of lung and 
other tobacco related cancers by implementation of strict tobacco control 
measures are important. Early detection of breast cancer should be encouraged in 
women through health education and prompting early diagnosis. Procedures like 
physical examination of the breast may prove to be useful early diagnostic tool in 
this context.
SECTION II
CHAPTER 1
INTRODUCTION
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CHAPTER ONE
INTRODUCTION
Breast cancer is the most common malignancy affecting women 
worldwide (Parkin, 2004), accounting for 25% of all new cases of cancer. One in 
eight to one in twelve women is likely to suffer from Breast cancer during her 
life-time in the developed countries and one in twenty two is likely to have the 
disease in developing countries. Breast cancer incidence rate varies atleast tenfold 
worldwide (Parkin et al., 2001) largely because of range of socio-economic, 
reproductive, hormonal, nutritional and genetic factors (Mcpherson et al., 2000). 
Areas of high-incidence include North America and Europe (Parkin et al., 2001). 
South-east Asia contributes over 1/5th of the worldwide prevalence of the disease 
with Pakistan having highest incidence among Asian population after Israel 
(Bhurgri et al., 2000). In India, breast cancer is the second common cancer in 
women after cervical cancer; however breast cancer has replaced cervical cancer 
as the leading site of cancer among women in Indian cities (ICMR, 2001).
Kashmir, which lies at an altitude of 1800-2400 km from the sea-level and 
borders the low-incidence country, India and the high-incidence area of Pakistan, 
is distinct from other areas in term of its unique geographical locale, intra-
community marriages, tradition, culture, food habits and ethnicity. Over the past 
few years, the valley has witnessed an increase in the incidence of breast cancer 
and threatens to overtake oesophageal cancer as the most common cancer among 
Kashmiri women. 
Breast Cancer refers to cancers originating from breast tissue, most 
commonly from the epithelial cells that line the milk ducts or the lobules that 
supply the ducts with milk (Jensen, 1976). Depending on wherein the glandular 
or ductal unit of the breast the cancer arises, it develops certain characteristics 
that are used to sub-classify breast cancer into types. Cancers originating from 
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ducts are known as ductal carcinomas and those originating from lobules are 
known as lobular carcinomas. The primary tumor begins in the breast itself but 
once it becomes invasive, it may progress beyond the breast to the regional 
lymph nodes or travel (metastasize) to other organ systems in the body and 
become systemic in nature. Cancer cells that remain confined to the boundaries of 
the lobular unit or the draining duct are classified as in situ or non-invasive. An 
invasive breast cancer is one in which there is dissemination of cancer cells 
outside the basement membrane of the ducts and lobules into the surrounding 
adjacent normal tissue. There are many different types of breast cancer, with 
different stages (spread), aggressiveness, and genetic makeup and the survival of 
the patient varies greatly depending on those factors (6).
Although many risk factors of the disease like ageing (Moolgavkar et al.,
1979), early menopause (Magnusson et al., 1998), alcohol consumption 
(Hamajima et al., 2002), radiation exposure (Grevias-Faqnou et al., 1999), 
tobacco use (Hamajima et al., 2002), obesity or over weight (Calle et al., 2003), 
physical activity (Bray et al., 2004), urbanization (McMichael et al., 1998), 
sedentary life style, dietary fat (Schulz et al., 2008), changes in reproductive 
patterns (Lord et al., 2008), such as delayed childbearing and having fewer 
children, nulliparity (Huo et al., 2008; Winer et al., 2000), no breast-feeding (Huo 
et al., 2008; Lord et al., 2008; Zeng et al., 2010), multiple abortions (Zeng et al.,
2010) and post-menopausal hormone replacement therapy (Beral, 2004), stand 
identified but a higher proportion of breast cancer is associated with a strong 
family history, with first-degree relatives of patients having an approximately two 
fold elevated risk (Colditz et al., 1993; Madigan et al., 1993).                                                                                                                           
Genetic susceptibility as a result of highly penetrant germ-line 
inactivation in cancer predisposing genes characterizes approximately 5-10% of 
breast cancer and 25% of the early onset of breast cancer (Palma et al, 2006; 
Wooster et al., 1994). Several genes have been identified that are associated with 
inherited susceptibility to breast cancer and have provided means to begin 
identifying individuals and families with an increased risk of cancer. One of the 
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most exciting and highly anticipated break through in cancer genetics was the 
cloning of BRCA1 and BRCA2 in early nineties (Wooster et al., 1994; Miki et 
al., 1994). BRCA1 and BRCA2 genes appear to account for the majority of 
hereditary breast cancer cases via autosomal dominant inheritance mechanism. 
Tumorigenesis in women with BRCA1 or BRCA2 mutations requires the loss or 
inactivation of the remaining wild-type allele, resulting in expression of a 
nonfunctional protein and a loss of cell cycle control and DNA repair 
mechanisms (Welcsh & King, 2001). BRCA1 and BRCA2 perform multiple 
discrete functions like regulates DNA repair, gene transcription and maintain 
genome integrity and tumor is initiated when genetic instabilities lead to 
increased mutations in these genes (Hall et al., 1990). In addition, many other 
genes like p53, ATM, CHEK2, MDM2, PTEN, the GADD repair group, the 
HER2/neu oncogene (Campeau et al., 2008; Lavin, 1998; Nechushtan et al., 
2009; Walsh et al., 2006) have also been implicated in the genesis of the disease. 
However, their involvement account for only a minor fraction of breast cancers. 
Some of these genes directly influence BC risk, whereas others are involved in 
the general processes of cancer growth and metastasis.              
In families with breast cancer consistent with hereditary breast cancer, it 
has been reported that BRCA1 mutations account for approximately 45% of 
families with significantly high breast cancer incidence and at least 80% of 
families with increased risk of both early-onset breast and ovarian cancer (Ford et 
al., 1994; Thompson & Easton, 2002). Whereas germ-line mutations of BRCA2 
are predicted to account for approximately 35% of families with multiple cases, 
early onset female breast cancer, and they are also associated with an increased 
risk of male breast cancer and ovarian cancer (Gayther et al., 1997; Thorlacius et 
al., 1996). In women the overall risk of breast cancer associated with mutations in 
the BRCA1 or BRCA2 gene is from 40% - 85% over a lifetime, whereas the 
lifetime risk in the general population is approximately 12.5%, which differ in 
populations (Japan (2%) and USA (14%)) (Antoniou et al., 2002; Begg, 2002). 
BRCA1 or BRCA2 mutation carriers (women) with a history of breast cancer 
Introduction
37
exhibit an elevated risk of contralateral breast cancer, at 40% to 60% (Begg, 
2002). BRCA1 and BRCA2 mutation carriers also have an elevated risk of 
ovarian cancer, ranging from 15% to 40%, compared with an approximate risk of 
2% in the general population (Ford et al., 1998). It is generally accepted, that 
carriers of mutations in BRCA1 or BRCA2 have an excessive risk for both breast 
and ovarian cancer, thus screening for and detection of BRCA1/BRCA2 
mutations may be helpful in determining the overall risk for the development of 
breast carcinoma, especially in families with hereditary cases. Individuals who 
are mutation carriers can undertake different surveillance strategies, 
chemoprevention interventions, or surgical prophylaxis for carcinomas of the 
breast and ovary. 
BRCA2 was the second breast and/ovarian cancer susceptibility gene to 
be discovered, mutated form of which when inherited strongly predispose to 
breast or breast and ovarian cancers (Sowter & Ashworth 2005; Wooster et al., 
1995). BRCA2 plays an important role in the error-free repair of DNA double 
strand breaks as well as transcriptional regulation (Davies et al., 2001; Moynahan 
et al., 2001; Pellegrini et al., 2002). In normal cells, BRCA2 ensures the stability 
of the cell’s genetic material (DNA) and helps to prevent uncontrolled cell 
growth. The spectrum of BRCA2 mutations has been characterized in different 
populations worldwide, with significant variation of the relative contribution of 
these genes to hereditary cancer between populations. Various population-based 
studies have shown population specific BRCA2 founder mutations and also 
variable number of novel mutations in different populations, and thus have 
defined high and low risk subsets for developing breast cancer based on ethnic 
origin (Oddoux et al., 1996; Thorlacius et al., 1997). Since Kashmiri women 
represent a cohort of genetically pure population, the mutational pattern of 
BRCA2 can serve as genetic marker for the identification of women who are at 
high risk of breast cancer.
Among the other genes likely to be involved in breast cancer is the gap-
junction gene Connexin43, which codes for a 43-kd gap-junction protein. 
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Connexin forms membrane spanning hexameric hemichannels called as 
connexons that, when in register in apposed cell membranes, couple to form a 
continuous hydrophilic channel through which ions, metabolites, and molecules 
involved in signal transduction can move from cell to cell. An array of many such 
channels constitutes a gap junction. Gap junctions initially identified to serve as 
passageways for the cell-to-cell exchange of low molecular weight growth 
regulatory molecules (Flagg-Newton et al., 1997; Loewenstein, 1981; 
Loewenstein & Kanno, 1966), have now been proposed to play an important 
regulatory role in cell growth, cell differentiation, cell apoptosis and tissue 
development (El Sabban et al., 2003; Gramsch et al., 2001; Ma & Dahl, 2006; 
Vinken et al., 2006; Wiszniewski et al., 2000). Down regulation of intercellular 
communication via gap junctions, either by down regulation or mistargeting of 
connexins (due to post-translational processing, germline or somatic mutations), 
appears to play a role in many types of pathologies, including cancer (Laird  et 
al., 2006; Mesnil et al., 2005; Severs et al., 2004). A large number of studies have 
indicated that connexins like Cx43, Cx32, Cx26 have tumor suppressing effects 
due to maintenance of cellular homeostasis via gap junctional intercellular 
communication and thus are players in the arena of growth regulation and in 
many types of cancer. (King et al., 2005; Naus et al., 1992). Studies on neoplastic 
cells using ultrastructural, biochemical and immunological means and by 
introduction of fluorescent or radio-active tracers have shown that the majority of 
neoplastic cells have fewer and smaller gap junctions, express less connexins and 
have reduced GJIC compared to their non-neoplastic counter-parts and up-
regulation of Cxs has been shown to restore normal phenotypes and retard tumor 
cell growth (Qin et al., 2002).
Connexin 43 is the predominantly expressed gap junction protein in 
normal breast tissue and plays an important role in normal mammogenesis, 
lactogenesis and involution (Cai et al., 1998; Monaghan et al., 1996). Studies 
have shown down-regulation of connexin 43 gap-junction protein in human 
breast cancer tissues or a relocalization of the connexin to intracellular 
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compartments, resulting in a predicted loss of GJIC compared to matched normal 
or benign breast tissue (Kanczuga- Koda et al., 2003, 2005; Laird et al., 1999; 
Lee et al., 1991; Wilgenbus et al., 1992).  Cx43 gap junction down-regulation has 
been observed in breast tissue at various stages of tumorigenesis, including 
Ductal carcinoma in situ (DCIS), invasive Infiltrating ductal carcinoma (IDC), 
and infiltrating lobular carcinoma (ILC) and restoration of gap-junction 
intercellular communication by up-regulation of connexins has been shown to 
restore normal phenotypes in vitro and reduce tumor growth in vivo (Hirschi et 
al., 1996; Mehta et al., 1991). Studies have also shown that down-regulation of 
endogenous Connexin 43 expression by small interfering RNA promoted a more 
aggressive phenotype in human breast cancer cell lines (Shao et al., 2005). 
Further more, data obtained with rat mammary carcinoma induced by DMBA 
also demonstrates that the loss of Connexin 43 gap junction is a common feature 
of mammary neoplastic transformed. Studies have also shown that Cx43 
expression in cancer cells leads to decrease expression of proteins involved in 
increased motility, invasion and metastases clearly indicating that it contributes to 
decreased metastasis in vivo. However the molecular mechanisms behind the 
down-regulation of Connexin 43 and contribution to development of primary 
tumor and its metastasis in breast remain elusive. A better understanding of the 
key events that lead to the down-regulation of connexins in breast cancer is 
necessary to gain information relevant to the designing of anti-cancer treatment 
models against breast cancer. Multiple mechanisms appear to be responsible for 
the down regulation of Connexin43 in breast neoplastic tissue, and one of the 
potent mechanisms can be mutations in gap-junctions genes.
We propose to study the sequence variations in breast cancer patients of 
the Kashmir region, and workout association of such variations (if any) with the 
disease phenotype. Despite the existence of a large population of breast cancer 
patients, there is a paucity of such kind of data from the state of the Jammu and 
Kashmir. The present study is therefore aimed to investigate the mutation status 
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of BRCA2 and Connexin 43 in Kashmiri breast cancer patients to verify its 
possible role in breast cancer incidence and development in Kashmiri population.
CHAPTER 2
REVIEW OF 
LITERATURE
Review Of Literature
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CHAPTER TWO
REVIEW OF LITERATURE
2.1 BREAST CANCER
2.1.1 DEFINITION   
Breast cancer is the formation of a malignant tumor that has developed 
from cells in the breast. Each breast has 15 to 20 sections called lobes, which 
have many smaller sections called lobules and these lobes and lobules are 
connected by thin tubes, called ducts. The malignant cells either originate in the 
lining of the milk glands or ducts of the breast (Jensen, 1976) and depending on 
where in breast the cancer arises, it will develop certain characteristics that are 
used to sub-classify breast cancer into types. The primary tumor begins in the 
breast itself but once it becomes invasive, it may progress beyond the breast to 
the regional lymph nodes or metastasize to other organ systems in the body and 
become systemic in nature (Cady, 1984; Jatoi, 1987). Breast cancer follows this 
classic progression though it often becomes systemic or widespread early in the 
course of the disease. When primary breast cancer spreads, it may first go to the 
axillary nodes leading to regional metastasis (Cady, 1984). Or it may proceed 
elsewhere either by lymphatic or blood-borne spread and the patient develops 
systemic metastasis that may involve a number of other organs in the body (Jatoi, 
1987). Favorite sites of systemic involvement for breast cancer are the lung, 
bones (Rose & Siegel, 2006), liver, skin and soft tissue (7). As it turns out, the 
presence of, and the actual number of, regional lymph nodes containing cancer 
remains the single best indicator of whether or not the cancer has become 
metastatic. Because tests to discover metastasis in other organs may not be 
sensitive enough to reveal minute deposits, the evaluation of the axilla for 
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regional metastasis becomes very important in making treatment decisions for 
widely this disease. If breast cancer spreads to other major organs of the body, its 
presence will compromise the function of those organs.
2.1.2  TYPES OF BREAST CANCER 
Breast cancer is considered as highly heterogeneous group of cancers 
arising from different cell types and each having its own clinical implications. 
Breast cancer can begin in different areas of the breast – the ducts, the lobules, or 
in some cases, the tissue in between. Depending on from where the cancer arises, 
breast cancer is divided into different types.
2.1.2.1  Non-invasive breast carcinoma
When breast tumors are discovered at an early stage, they are still small 
and confined. In such cases, cancer cells have not grown into the surrounding 
tissues and remain within the borders of a duct or lobule. These tumors are 
known as non-invasive or in situ tumors. In situ tumors are too tiny to form a 
'lump,' and so they usually are not felt or detected during a physical exam and are 
diagnosed by mammography. Non-invasive carcinomas include
2.1.2.1.1  Ductal carcinoma in situ (DCIS): DCIS also known as intraductal 
carcinoma or non-invasive ductal carcinoma starts inside the milk ducts and is the 
most common type of non-invasive breast cancer. DCIS isn’t life-threatening, but 
having DCIS can increase the risk of developing an invasive breast cancer later 
on. (Bellamy et al., 1993; Page et al., 1982). Each year, about 1.9% of women 
with high-grade DCIS develop invasive breast cancer after lumpectomy (Page et 
al., 1982). Thus, DCIS is a potential marker for invasive carcinoma.
2.1.2.1.2  Lobular carcinoma in situ (LCIS): LCIS also known as non-invasive 
lobular carcinoma usually occurs in women who have not undergone menopause. 
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Lobular means that the abnormal cells start growing in the lobules, the milk-
producing glands at the end of breast ducts. LCIS is a multifocal (located in more 
than one area) disease that typically affects both breasts in contrast to DCIS, 
which generally is unifocal or at least limited to one region of the breast. Because 
of the multifocal character of LCIS, women with this disease should receive 
careful examinations of both breasts. However, over 99% people with LCIS do 
not develop invasive breast cancer. (Frykberg et al., 1987; Singletary et al., 
1994).
2.1.2.2  Invasive Carcinomas
If breast cancer penetrates the membrane that surrounds the lobules or 
ducts, it is called an infiltrating or invasive carcinoma. Invasive carcinoma can 
grow into the supporting tissue between the ducts, blood vessels, lymph nodes,
and other structures within the breasts. Therefore, there is a greater chance that 
invasive carcinoma will metastasize, spreading throughout the body. Invasive 
carcinomas include
2.1.2.2.1  Ductal Invasive carcinomas: About 75% percent of all invasive breast 
cancers are ductal carcinomas (Li et al., 2003). Under the microscope, ductal 
carcinoma looks like a mass with poorly defined edges that have begun to extend 
into the surrounding tissue (Mai et al., 2000). As the cancer invades the fatty 
tissue around a duct, it causes the formation of fibrous, scar-like tissue (Harris et 
al., 1984). Such scar formation makes ductal carcinoma appear larger than it 
actually is. Depending upon the location of the tumor, the symptoms of invasive 
ductal carcinoma may include retraction (drawing inward) of the nipple or nipple 
discharge and skin changes such as wrinkling or dimpling.
2.1.2.2.2  Lobular Invasive carcinomas: These cancers make up approximately 
5% to 10% of all invasive breast cancers (Borst & Ingold, 1993; Li et al., 2003; 
Martinez & Azzopardi, 1979). ILC is characterized by small round cells that are 
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bland in appearance and have scant cytoplasm, which infiltrate the stroma in 
single file and surround benign breast tissues in a targeted manner (Fisher 1975; 
Martinez & Azzopardi, 1979). Lobular breast cancer is more difficult to detect by 
mammography because it may not occur as a distinct lump (Krecke & Gisvold 
1993; Yeatman et al., 1995). Instead, lobular carcinoma may appear as an 
irregular thickening in the breast. A small proportion of women (~5%) may 
develop lobular carcinoma in both breasts (Dixon et al., 1983; Du toit et al., 
1989; Lesser et al., 1982).
In addition to ductal and lobular carcinoma, three well recognized types 
of invasive breast cancer are: tubular cancers (slow-growing, tube-shaped 
cancers), medullary cancers (cancers that look like the medulla [gray matter] of 
the brain), and mucinous cancers (cancers that contain a mucous protein) (Diab et 
al., 1999; Li et al., 2003). 
2.1.2.2  Inflammatory carcinoma
It is a very serious, rapidly spreading type of tumor that accounts for 
about 1% of all breast cancers (Anderson et al., 2004; Wingo et al., 2004). It 
produces symptoms like swelling, redness, and skin warmth, which result from 
blockage of the skin's lymphatic vessels by cancer cells (Green et al., 2002; 
Taylor et al., 1938). Because of such symptoms, inflammatory carcinoma 
sometimes is confused with mastitis - a breast infection that may or may not be 
associated with breastfeeding and can be cured by antibiotics.
2.1.2.3 Paget's disease
Paget's disease of the nipple is a rare form of breast cancer in which 
cancer cells collect in or around the nipple. The cancer usually affects the ducts 
of the nipple first (small milk-carrying tubes), then spreads to the nipple surface 
and the areola (the dark circle of skin around the nipple). The nipple and areola 
often become scaly, red, itchy, and irritated (Kaelin, 2004). It usually strikes 
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middle-aged women and may occur in association with an underlying in situ or 
invasive ductal carcinoma of the breast (Kaelin, 2004).
2.1.3  SIGNS AND SYMPTOMS        
The following are the symptoms associated with breast cancer:
 The first noticeable symptom of breast cancer is typically a lump that 
feels different from the rest of the breast tissue. More than 80% of breast 
cancer cases are discovered when the woman feels a lump (6). The 
earliest breast cancers are detected by a mammogram (3). Lumps found in 
lymph nodes located in the armpits (6) can also indicate breast cancer. 
 Indications of breast cancer other than a lump may include changes in 
breast size or shape, skin dimpling, nipple inversion, or spontaneous 
single-nipple discharge. Pain (mastodynia) is an unreliable tool in 
determining the presence or absence of breast cancer, but may be 
indicative of other breast health issues (3, 6).
 Unexplained weight loss can occasionally herald an occult breast cancer, 
as can symptoms of fevers or chills.
 Symptoms of inflammatory breast cancer include pain, swelling, warmth 
and redness throughout the breast, as well as an orange-peel texture to the 
skin referred to as peau d’orange (Green et al., 2002; Taylor & Meltzer, 
1938).
 In Paget's disease of the breast, the syndrome presents as eczematoid skin 
changes such as redness and mild flaking of the nipple skin (Kaelin,
2004). As Paget's advances, symptoms may include tingling, itching, 
increased sensitivity, burning, and pain (Kaelin, 2004). There may also be 
discharge from the nipple. Approximately half of women diagnosed with 
Paget's also have a lump in the breast (Kaelin, 2004).
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 Bone or joint pains can sometimes be manifestations of metastatic breast 
cancer, as can jaundice or neurological symptoms. These symptoms are 
"non-specific", meaning they can also be manifestations of many other 
illnesses (8). Most symptoms of breast disorder do not turn out to 
represent underlying breast cancer. Benign breast diseases such as 
mastitis and fibroadenoma of the breast are more common causes of 
breast disorder symptoms (Shaaban et al., 2002). The appearance of a new 
symptom should be taken seriously by both patients and their doctors, 
because of the possibility of an underlying breast cancer at almost any age 
(6).
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2.1.4  STAGES OF BREAST CANCER
   Breast cancer staging is based on the TNM system, defined by the American Joint 
Committee on Cancer, which takes into account tumor (T) size, the extent of 
regional lymph node (N) involvement, and the presence or absence of metastasis 
(M) beyond the regional lymph nodes. Using this system, whose criteria and 
details are outlined in Table 2.1, breast cancer is staged from 0 to IV. Stage 0 
implies in situ cancer, while stages I to IV indicate invasive cancer, with IV
implying metastatic spread to distant organs.
“†” Size measurements are for the tumor’s greatest dimension.                                                                                                                                                                                                                   
“*”Includes microinvasion of 0.1 cm or less in greatest dimension.
Table 2.1: Criteria for staging breast tumors according to the American Joint Committee on 
Cancer’s TNM classification (Greene et al., 2002).
Primary Tumor
(T) †
Regional Lymph
Node Status  (N)
Distant Metastasis
(M)
  Stage Groupings
Carcinoma in situ No evidence of cancer in nearby nodes No Stage 0
Tumor ≤ 2 cm No evidence of cancer in nearby nodes No Stage I
No evidence of primary tumor
Tumor ≤ 2 cm*
Tumor > 2 cm but ≤ 5 cm
Metastasis to 1–3 nodes
Metastasis to 1–3 nodes
No evidence of cancer in nearby nodes
No Stage IIA
Tumor > 2 cm but ≤ 5 cm
Tumor > 5 cm
Metastasis to 1–3 nodes
No evidence of cancer in nearby nodes
No Stage IIB
No evidence of primary tumor
Tumor ≤ 2 cm*
Tumor > 2 cm but ≤ 5 cm
Tumor > 5 cm
Tumor > 5 cm
Metastasis to 4–10 nodes
Metastasis to 4–10 nodes
Metastasis to 4–10 nodes
Metastasis to 1–3 nodes
Metastasis to 4–10 nodes
No Stage IIIA
Tumor of any size with direct 
extension to chest wall or skin
Tumor of any size with direct 
extension to chest wall or skin
Tumor of any size with direct 
extension to chest wall or skin
No evidence of cancer in nearby nodes
Metastasis to 1–3 nodes
Metastasis to 4–10 nodes
No Stage IIIB
Any tumor designation Metastasis to > 10 nodes No Stage IIIC
Any tumor designation Any lymph node designation Yes Stage IV
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2.1.3  RISK FACTORS
   Following risk factors for breast cancer have been identified and unanimously 
agreed upon.
2.1.5.1  REPRODUCTIVE FACTORS
2.1.5.1.1 Menstrual history: Women who have had more menstrual cycles 
because they started menstruating at an early age (before age 12) and/or went 
through menopause at a later age (after age 55) have a slightly higher risk of 
breast cancer (Helmrich et al., 1983; Winer et al., 2000). This may be related to a 
higher lifetime exposure to the hormones like estrogen and progesterone                
(Henderson et al., 1988).
2.1.5.1.2 Parity, Reproductive history and Breast feeding: Parity and an early 
first full-term pregnancy (FFTP) both have been shown to decrease the long-term
breast cancer risk (Lambe et al., 1996; Sinha et al., 1988).  Nulliparous women are 
also at increased risk of acquiring breast cancer (Huo et al. 2008). Before 
pregnancy, mammary gland cells are in a vulnerable undifferentiated state but 
differentiate to functioning milk-producing structures during pregnancy which are 
refractory to carcinogenesis (Russo et al., 1994, 1997, 2001). It is thought that 
pregnancies and FFTP in particular, consecutively decrease the pool of vulnerable 
breast cells (Russo et al., 1994, 1997, 2001). The undifferentiated cells found in 
the breast of nulliparous women never undergoes through the process of 
differentiation, retaining a high concentration of epithelial cells that are targets for 
carcinogens and are therefore susceptible to undergo neoplastic transformation 
(Boulanger et al., 2005; Henry et al., 2004; Wagner et al., 2002). Breast feeding 
also reduces BC risk and is thought to exert its effects through hormonal 
mechanisms (Huo et al., 2008; Lord et al., 2008; Zeng et al., 2010). 
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2.1.5.1.3 Post-menopausal hormone therapy (PHT): This therapy also known 
as hormone replacement therapy (HRT) and menopausal hormone therapy (MHT), 
is used by many older women to relieve the symptoms of menopause and to help 
prevent osteoporosis (thinning of the bones). The long-term (more than five years) 
use of postmenopausal estrogen therapy (ERT) or combined estrogen/progestin 
hormone replacement therapy (HRT) may be associated with an increase in breast 
cancer risk (Porch et al., 2002; Beral, 2004).
2.1.5.1.4 Abortion/miscarriage history: Some studies have reported an 
increased risk of breast cancer among women who have had induced abortions 
(Newcomb et al., 1996; Zeng et al., 2010). In incomplete pregnancy, the breast is 
exposed only to the high estrogen levels of early pregnancy and thus may be 
responsible for the increased risk seen in these women. However, some other 
studies have found no association between abortions and increased risk of breast 
cancer (Erlandsson et al., 2003).
2.1.6.1 ENVIRONMENTAL AND LIFE STYLE FACTORS
2.1.6.1.1 Environmental pollutants: Certain compounds in the environment 
have been found to be associated with increased breast cancer risk (Cohn et al., 
2007; Engel et al., 2005; Romieu et al., 2000; Teitelbaum et al., 2007). For 
example, substances found in some plastics, certain cosmetics and personal care 
products, pesticides, and PCBs (polychlorinated biphenyls) seem to have such 
properties. 
2.1.6.1.2 Life-style: Studies have consistently shown that the risk of breast cancer 
is lower among physically active premenopausal women than among sedentary 
women (Bernstein et al., 1994; Friedenreich et al., 2001). Physical activity during 
adolescence may be especially protective, and the effect of physical activity may 
be strongest among women who have at least one full-term pregnancy.
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2.1.6.1.3 Exercise: A woman's exposure to estrogen is lowered by exercise, 
which affects the menstrual cycle and can inhibit ovulation. Research suggests 
that the less a woman ovulates (that is, the fewer ovulation cycles she has), the 
lower her risk of breast cancer. So exercise - with its apparent ability to affect 
estrogen and, likewise, ovulation - may indirectly lower the risk of breast cancer 
(Bray et al., 2004).
2.1.6.1.4 Alcohol Use and smoking: The risk of breast cancer is increased among 
women who consume alcohol or smoke (Atkinson, 2003; Chen et al., 2002; 
Hamajima et al., 2002; Palmer & Rosenberg, 1993). Studies have shown that 
consumption of more than two drinks a day leads to an increased level of estrogen 
in the blood leading to increased risk of breast cancer.
2.1.6.1.5 Dietary fat: There are conflicting results concerning the relationship 
between dietary fat and breast cancer. Many U.S. studies have found no 
association between the two; however, international findings suggest that breast 
cancer rates are minimal in countries where the standard diet is low in fat (Schulz 
et al., 2008). 
2.1.6.1.6 Radiation Exposure: A significantly increased risk of breast cancer has 
been found in women who have received radiation therapy in the chest area during 
childhood or young adulthood. This association has been observed both among 
atomic bomb survivors and among women who received high-dose radiation for 
medical purposes (Dershaw et al., 1992; Mattsson et al., 2002).
2.1.6.1.7 Body fat: Obesity has been consistently associated with an increased 
risk of breast cancer among postmenopausal women (Brown & Allen, 2002; Calle 
et al., 2003; Hirose et al., 2001). This relationship may be mediated again by
estrogen production. Fat cells produce some estrogen and obese postmenopausal 
women, therefore, tend to have higher blood estrogen levels than lean women.
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2.1.6.1.8 Race and ethnicity: Breast cancer is diagnosed more often in white 
women than Latina, Asian, or African American women (Frost et al., 1996; Joslyn 
et al., 2000). 
2.1.6.2  GENETIC FACTORS
2.1.6.2.1 Gender: Simply being a woman is the main risk factor for developing 
breast cancer (Kelsey & Gammon, 1990). The reason women develop breast 
cancer more is not merely because of more breast cells than men, but lies in the 
fact that their cells are constantly exposed to the growth-promoting effects of the 
female hormones estrogen and progesterone. Although men do develop breast 
cancer, the disease is about 100 times more common among women than men 
(Wu et al., 2002). 
2.1.6.2.2 Age: The chance of getting breast cancer goes up as a woman gets older 
(Edwards et al., 2002; Ries et al., 2000; Wu et al., 2002). About 1 out of 8 
invasive breast cancers are found in women younger than 45, while about 2 out of 
3 invasive breast cancers are found in women at an age 55 or older. 
2.1.6.2.3 Breast cancer: A woman who has breast cancer in one breast has a 3-
to 4-fold increased risk of developing a new cancer in the other breast or in 
another part of the same breast. (Hartmann et al., 2005).
2.1.6.2.4 Family history: A woman's risk of developing breast cancer is higher if 
her mother, sister, or daughter had breast cancer. The risk is also higher if one of 
her family member got the disease before age 40 (Claus et al., 2003). Having other 
relatives with breast cancer (in either her mother's or father's family) may also 
increase a woman's risk to the disease.
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2.1.6.2.5 Genetic Alterations: Genetic susceptibility to cancer is triggered in 
several ways; the best understood causal mechanism being due to inactivating 
germline mutations in tumor suppressors and/or oncogenes (Levine, 1998; 
Cooper, 1990). The genetic events affecting oncogenes often result in increased 
stimulatory function, whereas those affecting tumor suppressor genes may cause 
loss of inhibitory function.
Mutations targeting Oncogenes result in the hyper-activation of these 
genes in cancer cells, giving those cells new properties, such as hyperactive 
growth and division, recalcitrance against programmed cell death, loss of respect 
for normal tissue boundaries and the ability to become established in diverse tissue 
environments (Bishop, 1989; Varmus, 1989). This can be achieved by a number of 
simple molecular mechanisms, including point mutations that constitutively 
activate an enzyme, deletions that remove negative regulatory regions from 
proteins (Bishop, 1991), or increased expression resulting from promoter 
deregulation or from multiplication of the number of copies of the gene by a 
mechanism called amplification (Savelyeva & Schwab, 2001). Activation of an 
oncogene is a dominant mechanism, since alteration of a single allele is sufficient 
to confer a gain of function for onset of cancer progression.
Mutations targeting Tumor suppressor genes (TSGs) results in the loss 
of normal functions essential for the maintenance of normal proliferation, accurate 
DNA replication, control over the orientation and adhesion within tissues, and 
interaction with protective cells of the immune system. Loss of function of a tumor 
suppressor gene, is typically recessive (Fearon, 1998) and can happen due to gene 
inactivation mechanisms like mutations, methylation or loss of alleles (most often 
through the loss of entire chromosomal sections encompassing several dozen 
genes), small deletions or insertions that scramble the reading frame of the gene, 
transcriptional silencing by alteration of  the promoter region, or point mutations 
that change the nature of the residues that are crucial for the activity of the 
corresponding protein. TSGs are classified into two major groups; first group 
genes are nicknamed “gatekeepers” which are negative regulators of the cell-cycle, 
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acting as brakes to control cell division. The genes of the second group are called 
“care-takers” as their primary aim is not to control the speed or timing of cell-
division but rather its accuracy. Care-taker genes are usually involved in the DNA 
repair and in controlling genomic instability. Their inactivation does not enhance 
cell proliferation per se but primes the cell for rapid acquisition of further genetic 
changes (Kinzler & Vogelstein, 1997).
The combined activation of oncogenes and inactivation of tumor 
suppressor genes drives the progression of cancer. The most evident biological 
consequences of these alterations are autonomous cell proliferation, increased 
ability to acquire genetic alterations, due to dysregulated DNA repair, ability to 
grow in adverse conditions due to decreased apoptosis, capacity to invade tissues 
locally and to form distant metastasis, and ability to activate the formation of new 
blood vessels (Bishop, 1989; Varmus, 1989). None alone is sufficient in itself, but 
cancer arises when these five biological phenomena interact together into a chain 
of coordinated events that profoundly modifies the normal cellular pattern of 
growth and development.                          
Genetic susceptibility as a result of highly penetrant germ line 
inactivation in cancer predisposing genes have a risk of approximately 5-10% for 
breast cancers, 10% for ovarian cancer and 25% for the early onset of breast 
cancer (Palma et al., 2006).The dissection of the genetics of BC gained momentum 
more than 10 years ago with the identification of the two main BC associated 
tumor suppressor genes BRCA1 and BRCA2. (Claus et al., 1996; Hall et al., 1990; 
Miki et al., 1994; Wooster et al., 1995). In addition, many other genes have been 
found to associate with BC, including p53, ATM, CHEK2, MDM2, PTEN, the 
GADD repair group, the HER2/neu oncogene, etc (Campeau et al., 2008; Lavin,
1998; Nechushtan et al., 2009; Walsh et al., 2006). However, mutations in these 
genes account for only a minor fraction of breast cancers. Some of these genes 
directly influence BC risk, whereas others are involved in the general processes of 
cancer growth and metastasis. 
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2.1.6.2.5  BRCA2
BRCA2 is a well established BC susceptibility gene, mutated form of 
which when inherited strongly predispose to breast cancers (Welcsh & King, 
2001). Germ-line mutations of BRCA2 are predicted to account for approximately 
35% of families with multiple cases, early onset female breast cancer, and they are 
also associated with an increased risk of male breast cancer and ovarian cancer 
(Gayther et al., 1997; Thorlacius et al., 1996). The candidate tumor suppressor 
gene BRCA2 was discovered in 1994 by Professor Michael Stratton and Dr 
Richard Wooster (Institute of Cancer Research, UK) and was localized on long (q) 
arm of chromosome 13 at position 12.3 by linkage analysis and cloned in 1995 
(Wooster et al., 1994, 1995). More precisely, the BRCA2 gene is located from 
base pair 31,787,616 to base pair 31,871,804 on chromosome 13. The BRCA2 
gene spans approximately 70kb in the genome and is composed of 27 exons. The 
BRCA2 cDNA consists of 11,385 bp and encodes a protein of 3,418 amino acids 
(385kDa molecular weight). Unlike most human genes, the coding sequence is AT 
rich (>60%).
The protein encoded by this gene is involved in the repair of 
chromosomal damage with an important role in the error-free repair of DNA 
double strand breaks as well as transcriptional regulation (Scully & Livingston, 
2000; Zheng, 2000). In normal cells, BRCA2 help ensure the stability of the cell’s 
genetic material (DNA) and help prevent uncontrolled cell growth. The BRCA2 
gene acts as a classical tumor suppressors and can be rendered nonfunctional in 
cancer cells as a result of germline mutations in any one of the second allele (the 
Knudson two hit hypothesis). 
The BRCA2 is essential for homologous DNA recombination (HDR), a 
process for the error-free repair of DNA double-stranded breaks (DSBs), in the 
cells of higher eukaryotes (Kojic et al., 2002; Moynahan et al., 2001). BRCA2 
orthologues exist in most eukarya, with the notable exception of yeast (Lo et al.,
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2003). These breaks can be caused by natural and medical radiation or other 
environmental exposures, and also occur when chromosomes exchange genetic 
material in preparation for cell division. Loss of these controls following BRCA2 
inactivation may be a key event leading to genomic instability and tumorigenesis.                     
The BRCA2 protein is known to interact with major proteins involved in 
DNA repair by homologous recombination and, in particular the RAD51 protein 
(recombinase) (Chen et al., 1998). RAD51 family members are homologous to 
the bacterial RecA and yeast Rad51 (Yang et al., 2005). The protein is highly 
conserved in most eukaryotes, from yeast to humans (Davies et al., 2001; 
Pellegrini et al., 2002; Yuan et al., 1999). BRCA2 is shown to regulate both the 
intracellular localization and DNA-binding ability of this protein (Sharan et al., 
1997; Yuan et al., 1999). RAD51 is indispensable in catalyzing the primary 
reaction required for HR, and its association with BRCA2 is required to facilitate 
this effect (Davies et al., 2001). The primary reaction begins when broken DNA 
is end-resected to generate ssDNA, upon which RAD51 oligomerizes to form an 
active nucleoprotein filament and this multimerization is controlled by its 
interaction with BRCA2 in vertebrates. The RAD51 nucleoprotein filament 
catalyzes strand exchange by invading and pairing with a homologous DNA 
duplex, used as a template for repair. Several functions have been ascribed to the 
BRCA2-RAD51 interaction, both in vivo and in vitro, in regulating these events. 
They include the sequestration of RAD51 in undamaged cells and its 
mobilization after damage (Yu et al., 2003), targeting of RAD51 to DSBs (Yuan 
et al., 1999), control of RAD51 oligomerization (Davies et al., 2001; Pellegrini et 
al., 2002) and modulation of sequential DNA substrate selection by RAD51, a 
process that orders the strand exchange reaction itself (Carreira et al., 2009; 
Shivji et al., 2009). 
BRCA2 utilizes two motifs with apparently distinct properties to bind 
RAD51. A conserved region in the exon11 encodes short sequence of eight  35-
peptide motifs called BRC repeats which are conserved in both their sequence 
and spacing. Each of the eight BRC repeats in human BRCA2, despite only 
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subtle sequence variation, exhibits a varying affinity for RAD51 (Chen etal., 
1998; 1999; Wong et al., 1997). BRC3 and BRC4 have the strongest interaction 
with RAD51 (Davies & Pellegrini, 2007; Esashi et al., 2007; Saeki et al., 2006).  
BRC repeats, in isolation, or in the context of BRCA2 , bind RAD51 complexes 
on DNA (Galkin et al., 2005; Shivji et al., 2006) and differentially regulate
RAD51 assembly on ssDNA versus dsDNA, promoting loading onto ssDNA, 
whilst concurrently impeding loading onto dsDNA, thereby stimulating strand 
exchange (Carreira et al., 2009; Shivji et al., 2009). A second region at the 
extreme carboxyl (C) terminus binds RAD51 (Mizuta et al., 1997; Sharan et al., 
1997) in a manner regulated by the phosphorylation of a key serine residue 
(Ser3291 in human BRCA2) by cyclin-dependent kinase (CDKs) (Esashi et al., 
2005) and is shown to stabilize RAD51 oligmeric assemblies in vitro both on and 
off DNA. Recent cellular studies suggest that the C-terminal RAD51-binding 
region is dispensable for the execution of HDR in vivo, and instead, coordinates
the termination of HDR with entry into mitosis (Ayoub et al., 2009). Thus, the 
binding of BRC repeats of BRCA2 to RAD51 may be the primary mode of 
interaction between the two proteins relevant to HDR.
Cells that are defective for BRCA2 are hypersensitive to agents that 
crosslink DNA strands or that produce breaks in double-stranded DNA, such as 
cisplatin and mitomycin C as RAD51 foci do not form after DNA damage 
(Moynahan et al., 2001; Yuan et al., 1999). In these cells, double-strand breaks 
are repaired by an error-prone mechanism such as non-homologous end joining 
leading to chromosomal rearrangements (Patel et al., 1998; Yu et al., 2000). The 
resulting chromosomal instability is a crucial feature of carcinogenesis. The 
levels of expression of BRCA1, BRCA2 and RAD51 increase in cells when they 
enter S phase, indicating that they function during or after DNA replication. So, 
BRCA1 and BRCA2 function in a common pathway that is responsible for the 
integrity of the genome and the maintenance of chromosomal stability 
(Venkitaraman, 2002). Studies have shown that exogenous BRCA2 expression in 
cancer cells inhibits p53’s transcriptional activity, and RAD51 co-expression 
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enhances inhibitory effects of BRCA2 (Marmorstein et al., 1998). Studies have 
also indicated that RAD51 physically associates with the p53 tumor suppressor
protein (Buchhop et al., 1997). 
Fig. 2.1: The BRCA2-RAD51 interaction in DSB repair (Lord & Ashworth, 2007).
These findings demonstrate that BRCA2 physically and functionally 
interacts with two key components of cell cycle control and DNA repair 
pathways and therefore participates with p53 and RAD51 in maintaining genome 
integrity (Marmorstein et al., 1998).
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Attempts to discover other proteins capable of interacting with BRCA2 
led to the identification of DSS1 (deleted in split-hand/split-foot syndrome 1), a 
highly acidic 70 residue polypeptide. The DNA repair activity of BRCA2 is 
regulated by DSS1 that seems to function as a necessary cofactor (Kojic et al., 
2003). DSS1 binds to the carboxy- terminal region of BRCA2 (distal to the BRC 
region) which also includes the NLS (Marston et al., 1999). BRCA2 localization 
to nuclear foci requires its association with the partner and localizer of BRCA2 
(PALB2), mutations in which are associated with cancer predisposition (Xia et 
al., 2006).  PALB2 supports BRCA2 stability and determines its localization in 
the nucleus after DNA damage (Xia et al., 2006). Relocation of PALB2 and 
BRCA2 to damaged chromatin is regulated by BRCA1 protein (Zhang et al., 
2009). These three proteins form a complex in which PALB2 acts as a bridge 
between BRCA1 and BRCA2 (Zhang et al., 2009). In cells depleted of PALB2, 
DNA repair pathway dependent on the BRCA1/2 is disrupted (Xia et al., 2006; 
Zhang et al., 2009). Deletion mapping has localized the PALB2 – interacting 
region of BRCA to residues 10-40 at the N-terminus of the protein (Xia et al., 
2006). The discovery of PALB2 as a crucial factor in localizing BRCA2 to sites 
of DNA damage provides the main role of amino terminal region of BRCA2 is to 
provide a binding site for PALB2 (Oliver et al., 2009).
BRCA2 possesses a putative transcriptional activation domain in exon 3, 
suggesting a role of BRCA2 in the regulation of gene expression and chromatin 
remodelling (Milner et al., 1997). Its involvement in transcriptional activation 
(Fuks et al., 1998; Milner et al., 1997), is reinforced by the discovery of EMSY, a 
protein able to interact with chromatin-regulatory proteins, as a binding partner 
for the BRCA2 (exon3) N-terminus (Hughes-Davies et al., 2003). When EMSY
protein is overexpressed, it inhibits transcriptional activation of BRCA2. The 
PALB2–binding site on BRCA2 directly overlaps that of EMSY (Hughes-Davies 
et al., 2003). Tumors with EMSY amplifications show chromosomal instability 
and mitomycin-C sensitivity characteristic of cells defective in BRCA2 or 
PALB2 (Raouf et al., 2005; Turner et al., 2004; Xia et al., 2006). BRCA2 also 
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regulates the activity of other genes and plays a critical role in embryo 
development. BRCA2 has been shown to interact with BRE (Dong et al., 2003), 
Filamin (Yuan and Shen, 2001), Replication protein A1 (Wong et al., 2003), 
BRCC3 (Dong et al., 2003), BARD1 (Dong et al., 2003; Ryser et al., 2009), 
FANC G (Hussain et al., 2003), and BCCIP (Liu et al., 2001). 
Germline mutations in the BRCA2 gene are associated with an increased 
susceptibility to breast cancer (in both males and females) and they also confer an 
increased risk of early onset ovarian, prostate, and pancreatic cancer. Mutations 
are distributed throughout the entire coding region of BRCA2 and to date 
numerous deleterious mutations have been reported. BRCA2 mutations are 
usually insertions or deletions of a small number of DNA base pairs in the gene 
or are nonsense mutations that lead to the introduction of a stop codon (Ford et 
al., 1998). However 38% of BRCA2 mutations are missense mutations that alter
one amino acid, but do not truncate the protein and are of uncertain significance. 
These mutations invariably generate a shortened (truncated) and non-functional 
BRCA2 protein. As a result of these mutations, the protein product of the BRCA2 
gene is abnormal and does not function properly. 
Wooster et al., were first to identify 6 different germ line mutations in the 
BRCA2 gene in families with BC, each causing serious disruption to the open 
reading frame of the transcriptional unit (Xia et al., 2001). Since then, over 300 
distinct mutations in BRCA2 have been described. The spectrum of BRCA2 
mutations has been characterized in different populations worldwide, with 
significant variation of the relative contribution of these genes to hereditary 
cancer between populations. Various population-based studies have shown 
population specific BRCA2 founder mutations and also variable number of novel 
mutations in different populations, and thus have defined high and low risk 
subsets for developing breast cancer based on ethnic origin (Oddoux et al., 1996; 
Thorlacius et al., 1997). Uniquely, amongst Jewish Ashkenazi individuals, one 
founder mutation 6174delT in BRCA2 account for the majority of cases in high-
risk families (Oddoux et al., 1996). Founder mutations have also been identified 
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in Icelandic and Polish populations. The spectrum of mutations also varies 
between populations, with some showing a high frequency of unique mutations, 
for example in Italy (Santarosa et al., 1998, 1999). Population specific mutations 
have also been described in the Netherlands (Peelen et al., 1997), Sweden 
(Hakansson et al., 1997), France (Stoppa et al., 1997), Spain (Diez et al., 2003) 
and other countries (Szabo and King, 1997).
Table 2.2: Different examples of founder mutations in the BRCA2 gene.
In addition, limited data indicate that the frequencies of specific BRCA2 
mutations may vary among individual racial and ethnic groups in the United 
States, including African Americans, Hispanics, Asian Americans, and non-
Hispanic whites (John et al., 2007; Malone et al., 2006; Vogel et al., 2007).
Population or subgroup BRCA2 mutation(s)
Ashkenazi Jewish 6174delT (Oddoux et al., 1996)
Dutch 5579insA (Verhoog et al., 2001)
Finns T8555G, 999del5 (Huusko et al., 1998)
Finns 8765delAG (Tonin et al., 1999)
Germans C61G (Backe et al., 1999)
Hungarians 9326insA (Van Der Looij et al., 2000)
Icelandics 999del5 (Thorlacius et al., 1996; Thorlacius et al., 1997)
Italians 8765delAG (Pisano et al., 2000)
Pakistanis 3337C>T (Liede et al., 2002)
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The Fanconi – anemia: FA is a rare recessive disease of childhood that 
features skeletal abnormalities, abnormal skin pigmentation, short stature and 
micropthalmia (Grompe & Andrea, 2001; Joenje & Patel, 2001). People who 
have two mutated copies of the BRCA2 gene have FA (Howlett et al., 2002). 
This condition is caused by extremely reduced levels of the BRCA2 protein in
cells, which allows the accumulation of damaged DNA. Patients with FA are 
prone to several types of leukemia; solid tumors, particularly of the head, neck, 
skin, and reproductive organs; and bone marrow suppression (reduced blood cell 
production that leads to anemia). 
Breast cancer incidence rate varies atleast tenfold worldwide (Parkin et 
al., 2001) largely because of range of socio-economic, reproductive, hormonal, 
nutritional and genetic factors (Mcpherson et al., 2000). The high-incidence areas
include North America and European countries (Parkin et al., 2001). South-east 
Asia contributes over 1/5th of the worldwide prevalence of breast cancer with 
Pakistan having highest incidence among Asian population after Israel (Bhurgri 
et al., 2000). In India, although overall incidence of BC in Indian population is 
low compared to Western populations (ASR of 23.5 vs. 90.7), the incidence of 
early onset disease (<40yrs) does not show significant geographic variation (ASR 
range worldwide of 12-33), suggesting that in the Indian population a greater 
proportion of BC is due to early onset disease compared to Western populations 
(Parkin et al., 1997). According to the  National Cancer Registry Project (NCRP) 
based on cancer registries at six hospitals, the average age of patients was found 
to range from 44.2 yrs (Dibrugarh) to 49.6 yrs (Bangalore and Chennai) 
(Jussawalla and Jain, 1997). Kashmir, which lies at an altitude of 1800-2400 km 
from the sea-level and borders the low-incidence country, India and the high-
incidence area of Pakistan, is distinct from other areas in term of its unique 
geographical locale, intra-community marriages, tradition, culture, food habits 
and ethnicity. Over the past few years, the valley has witnessed an increase in 
incidence and occurrence of breast cancer in its unexplored ethnic population. In 
Kashmiri women, breast cancer is the second most common cancer after uterine 
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cervix. The age adjusted rate as per our hospital records is approximately 12.6 per 
105 individuals per year with male to female ratio 0.02:1 (personal 
communication). The average age at onset of disease is lower (than western and 
other parts of India) and familial and breast cancer cases are also prevalent in the 
valley.    
Despite the large number of BRCA2 gene mutations reported worldwide, 
only few reports on the prevalence of BRCA2 mutation in India are available. 
Valarmathi et al., (2003) has reported three deleterious BRCA2 mutations 
including three frame shift mutations (c.5227dupT, c.5242dupT, c.6180dupA) 
and four novel missense variants in BRCA2. On analyzing a group of patients 
with a family history of breast and/or ovarian cancer and early onset BC, Raj 
Kumar et al., (2003) has reported one non-sense mutation in BRCA2 gene. In 
2006, Saxena et al., (2002) have reported three pathogenic protein-truncating 
mutations unique to Indian women (6376insAA in exon 11, 8576insC in exon 19, 
and 9999delA in exon 27) along with one missense mutation (A2951T), and one 
silent substitution (1593A>G) in BRCA2 in a cohort of 204 Indian BC patients. 
Mutation analysis of BRCA2 gene in 102 breast/ovarian cancer patients from 96 
different breast ovarian cancer families has identified 16 distinct germ line 
alterations in 27 individuals (26.47%) of which 11 were (69%) in exon 11. It was 
Saxena et al., (2006), who first attempted to analyze BRCA2 gene in North India 
and reported sequence variant in exon 18 (8345A>G) of BRCA2 resulting in a 
conservative substitution of asparagine to serine substitution at codon 2706 
(N2706S) and these missense variants likely represent population-specific 
polymorphisms. There is a further need of screening large number of samples 
from Indian population to investigate the role of BRCA2 gene mutations in the 
high-risk group of familial as well as early onset cases, which forms the largest 
group of breast cancer patients in the Indian population. Conversely, the impact 
of BRCA2 mutations on prognosis and survival of breast cancer patients is still 
debated in Indian population as compared to other populations where its use in 
screening of people which are at high of breast cancer has already started.
Review Of Literature
63
2.1.6.2.6  CONNEXIN 43
The formation of multi-cellular organisms necessitated the development 
of different forms of cell-cell communication to coordinate the activity of 
different groups of cells. Specialized but distinct structures have evolved 
independently to provide direct cell-to-cell communication in plants 
(plasmodesmata - Meiners et al., (1988)), fungi (septal pores – Belozerskaya, 
1998) and animals (gap junctions - Finbow et al., 1983). In animals, the 
maintenance of this homeostatic balance is controlled by the global interplay 
between three major communicative networks, namely extra-, intra- and 
intercellular mechanisms. Direct intercellular communication is mainly mediated 
by gap-junctions. Gap- junctions are intercellular channels that typically gather in 
groups of 10-10,000 so called plaques, at the membrane surface. They arise from 
the interaction of two opposing hemi-channels or connexons, one contributed by 
each communicating cells and the connexon is in turn composed of six connexin 
proteins (Bruzzone et al., 1996; White & Paul., 1999). In humans, more than 
twenty connexin species have yet been characterized. Connexin proteins either 
assemble into a hemichannel with either identical connexin subunits (homomeric) 
or different connexins (heteromeric) although only certain combinations are 
allowed (Falk et al., 1997; Segretain & Falk, 2004).   
Historically, these structures have been described as a particular group of 
cell junctions being specialized in the control of direct exchange of essential 
cellular metabolites like secondary messengers, ions and other small molecules of 
<1,000 Da between adjacent cells (Flagg-Newton et al. 1997; Loewenstein, 1981; 
Loewenstein & Kanno, 1966). However studies have shown now that gap 
junctions play a crucial role in various physiologic functions such as regulation of 
cell proliferation, cell differentiation, cell apoptosis and tissue development (El 
Sabban et al., 2003; Gramsch et al., 2001; Ma & Dahl, 2006; Vinken et al., 2006; 
Wiszniewski et al., 2000). Down regulation of intercellular communication via 
gap junctions, either by down regulation or mistargeting of connexins (due to 
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post-translational processing, germline or somatic mutations), appears to play a 
role in many types of pathologies, including cancer (Laird  et al., 2006; Mesnil et 
al., 2005; Severs et al., 2004).
Cx43 is the most widely expressed connexin being present in at least 34 
tissues and 46 cell types (Laird, 2006), and it is the predominant connexin 
expressed in most cell lines. It is known as the “heart gap junction protein” since 
it was first identified in heart muscle tissue (Beyer et al., 1987). The human Cx43 
gene is located at position 6q22.3 while there is also Cx43 processed pseudogene 
located on chromosome 5, which has got all the features of an expressed gene 
(Fishman et al., 1991). Cx43 has a common gene structure, consisting of two 
exons separated by one intron sequence. The intron, which is of variable length, 
is situated within the 5'-untranslated region, while the second exon contains the 
connexin coding sequence, and the 3'-untranslated region (Willecke et al., 2002). 
The Cx43 gene sequence remains relatively conserved among species, indicating 
its presence is very important for survival, as shown by Cx43 knockout mice 
dying early in development because of heart malformations (Reaume et al., 
1995). The C-terminal region of the Cx43 contains most of the regulatory and 
protein-protein interaction domains. Mice that are engineered to lack the C-
terminus of Cx43 die shortly after birth (Maass et al., 2004). The C terminus of 
Cx43 protein which is approximately 150 amino-acids long, contains multiple
serine/ tyrosine residues that are phosphorylation targets for various kinases 
including protein kinase A (PKA) (Yogo et al., 2006), protein kinase C (PKC) 
(Solan & Lampe, 2008)  p34cdc2/cyclin B kinase (p34cdc2) (Kanemitsu  et al., 
1998), casein kinase 1 (CK1) (Cooper & Lampe, 2002), mitogen-activated 
protein kinase (MAPK) (Cameron et al., 2003; Norris et al., 2008), and p60src 
kinase (src) (Loo et al., 1995). Phosphorylation of these sites is responsible for 
the regulation of GJ channel gating as well as GJ trafficking and degradation. 
Cx43 does not contain serine residues in its cytoplasmic loop, and neither there 
are any reports of phosphorylation of the N-terminal domain of connexin43. The 
C-terminal of Cx43 serves as an interactive platform for a variety of cellular 
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proteins which are participants in the field of growth control; their interaction 
(and regulation of the interaction) with Cx43, or other connexins anchored to the 
plasma membrane may affect their subcellular localization and thus their sites of 
action.
Initially all effects of connexin were attributed to direct cell to cell 
diffusion. However some of the connexin functions seem to occur unrelated to 
channel function.  Cx43 has been shown to inhibit cell proliferation when GJC
was blocked by pharmacological inhibitors, or channel formation is prevented
(Moorby & Patel, 2001). In addition, Cx43 point-mutants that did block GJC still 
reduced cell growth, and expression of the C-terminal tail alone gave similar 
results. Studies have shown that Cx43 over-expression can inhibit cell 
proliferation, accompanied by the decreased stability of Skp2, a protein involved 
in cell cycle regulation. (Zhang et al., 2003). Studies have also shown that the 
non-channel forming carboxy-terminal domain of Cx43 decreases cell 
proliferation as efficiently as the full length Cx43. The binding sites through 
which different proteins interact with the gap junction lie in the connexin 
molecule’s cytoplasmic carboxy terminal (CT) domain (Giepmans, 2004; Hunter 
et al., 2005). This domain is well known to house a series of functionally 
important sites, notably those involved in channel gating and those for 
phosphorylation and thus consists a main and important part of Cx43.
Loss of Cx43 has been shown to correlate with tumorigenesis (Yamasaki 
et al., 1995), and its upregulation has been shown to restore normal phenotypes in 
vitro and reduce tumor growth in vivo (Huang et al., 1998; Rose et al., 1993). 
Cx43 expression is known to be reduced in most cancer cell types, like epithelial, 
endothelial, mesothelial, neuroblastoma, breast and in many other cell types 
(Holder et al., 1993; Goodenough et al., 1996; Krutovskikh et al., 1994; Trosko et 
al., 2003; Yamasaki et al., 1995). In most cases, the loss of Cx43 mediated GJIC 
is due to a reduction in both protein and RNA levels. However, Cx43 trafficking 
to the cell membrane can also be ineffective, leading to the accumulation of 
cytoplasmic Cx43 that never forms GJs (Krutovskikh et al., 2000). Moreover, 
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other studies have suggested that the rate of Cx43 degradation can also determine 
the overall intracellular Cx43 level (Musil et al., 2000). The frequent impairment 
of Cx43 in early transformation (Yamasaki et al., 1995) suggests its aberrant 
expression is involved in the process of carcinogenesis and its expression is 
disadvantageous to cancer cell survival. It has long been shown that Cx43 over-
expression leads to the reversal of the differentiation phenotype to that usually 
seen in normal cells and inhibition of neoplastic potential (Chen et al., 1995; 
King et al., 2000; Koffler et al., 2000). 
Connexin 43 is the predominant gap-junction protein expressed in normal 
breast tissue and plays important role in normal mammogenesis, lactogenesis and 
involution (Monaghan et al., 1996). Cx43 is not expressed in normal breast stem 
cells but is expressed in the normal breast epithelial cells derived from these 
breast stem cells (Chang et al., 2001; Nomata et al., 1996; Trosko et al., 2000).
Studies have shown that Cx43 is down regulated at the mRNA and protein level 
in human breast tumors and several human mammary tumor cell lines (Lee et al., 
1992). Decreased expression of connexin gap junctions is seen in breast cancer at 
various stages of progression and restoration of gap-junction intercellular 
communication by up-regulation of connexins has been shown to restore normal 
phenotypes in vitro and reduce tumor growth in vivo (Hirschi et al., 1996; Laird 
et al., 1999). Various studies have shown that down-regulation of Cx43 plays role 
in primary tumor formation as well as its metastasis in breast tissue.   
Primary breast cancer is generally comprised of tumor cells and 
surrounding connective tissue. This arrangement creates multiple cell-cell 
interactions among tumor cells and between tumor cells and normal neighboring 
stromal cells. Among various patterns of cell-cell interactions, GJIC involving 
Cx43 is considered among the earliest alterations associated with malignant cell 
transformation. Studies have shown down-regulation of connexin 43 gap-junction 
in human breast cancer tissues compared with the non-neoplastic breast tissue 
surrounding primary tissue and re-expression of Cx43 reverses the malignancy of 
human mammary carcinoma cells (Laird et al., 1999; Naus et al., 1992;
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Zhongyong et al., 2008). Furthermore, data obtained with rat mammary 
carcinoma induced by DMBA also demonstrates that the loss of connexin 43-gap 
junction is a common feature of mammary neoplastic transformed. Reexpression 
of Cx43 suppressed the cancer phenotype, a regained ability to differentiate into 
three-dimensional (3D) structures in the presence of a basement membrane in 
human mammary carcinoma cells, MDA-MB-435 and reduction of tumor-growth 
in animal models (Qin et al., 2002; Zhongyong, 2008). Studies have also shown 
that down-regulation of endogenous Connexin 43 expression by small interfering 
RNA promoted a more aggressive phenotype in human breast cancer cell lines 
(Shao et al., 2005). In this study, it was seen Cx43 protein reduced fibroblastic 
growth factor receptor (FGFR) expression and possibly affected the expression of 
other proteins involved in tumor progression. Importantly, not only has the over-
expression of Cx43 or Cx26 been found to restore growth control in human breast 
tumor cells, but connexin-expressing tumor cells partially revert to a less 
malignant phenotype (Hirschi et al., 1996).
Recent studies have also shown Cx43 upregulation by the drugs genistein 
and quercetin leads to GJIC-independent inhibition of cell proliferation (Conklin 
et al., 2007). Cx43 plays role in tumorigenesis probably by inhibiting 
angiogenesis independently of cell communication as when Cx43 expression was 
inhibited by RNAi in breast cancer Hs578t cells, resulting in faster growth and 
increased aggressiveness of the cells, TSP-1 expression was reduced while 
expression of proangiogenic vascular endothelial growth factor was increased 
(Shao et al., 2005). A similar shift in the balance toward antiangiogenic factors 
was observed in MDA-MB-231 cells overexpressing Cx43, and conditioned 
media from these cells inhibited in vitro endothelial cell tubulogenesis and 
migration (McLachlan et al., 2006). Additionally, xenografts of Cx43-
overexpressing MDA-MB-231 cells showed reduced tumor angiogenesis. 
Altogether these results suggest that Cx43 acts as a tumor suppressor by 
mechanisms related to cell proliferation, migration and angiogenesis, supporting 
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a causal relationship between physiologic changes in Cx43 levels and aggressive 
malignant breast tumor cell phenotypes.
Tumor metastasis is a multi-step process that involves the dissociation of 
tumor cells from the primary tumor followed by their entry into the circulation, 
extravasation from the vascular system and proliferation into tumor masses at 
secondary tissue sites. Both cell-cell and cell-matrix interactions are important 
regulators at different stages of this metastatic cascade (Cairns et al., 2003). 
Down-regulation of connexins has shown to promote metastasis as exogenous 
expression of the breast metastasis suppressor 1 gene in MDA-MB-435 cells led 
to upregulation of Cx43 and restoration of GJIC, providing evidence that 
connexins act as tumor suppressors in metastasis (Saunders et al., 2001). 
Functional in vitro studies have observed that Cx26 and Cx43 expression leads to 
a decrease in the cell’s migratory potential and ability to invade through a 
basement membrane matrix (Momiyama et al., 2003) accompanied by a slight 
reduction in matrix metalloproteinase activity (Kalra et al., 2006). Additionally, 
studies have also shown that the number of metastases to lungs was reduced in 
mice injected with Cx43 expressing breast cancer cells relative to mice injected 
with vector controls (Zhongyang et al., 2008).
The movement of cancer cells across the endothelial cell barrier as they 
move in and out of the blood vessels has been shown to be a key step in 
metastasis and studies have shown that connexins play an important role in tumor 
cell vascular intravasation and extravasation (Zhou et al., 2008). In one study, 
GJIC was reduced in endothelial cells when they were co-cultured with breast 
cancer cells, presumably weakening cell-cell contacts and making it easier for the 
cells to cross the endothelial barrier during both intravasation and extravasation 
(Cai et al., 1998). Another study showed that overexpressing Cx43 in GJIC-
deficient HBL100 breast cancer cells allowed them to form heterocellular 
junctions capable of dye transfer with cells from a human microvascular 
endothelial cell line that expresses Cx43 and this increased tumor cell diapedesis.
This increase in transendothelial migration was blocked when the endothelial 
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culture was pretreated with GJIC inhibitors or when the breast cancer cells 
expressed a membrane localizing, nonfunctional chimeric mutant of Cx43 
(Pollmann et al., 2005). This study implies that both homocellular GJIC in the 
endothelium and heterocellular GJIC between breast cancer cells and the 
endothelium facilitate transendothelial migration. A series of studies performed 
on the effects of metastatic breast cancer cells on osteoblast differentiation 
performed with MDA-MB-231 and MC3T3-E1 cells showed inhibition of 
osteoblast differentiation by conditioned medium from breast cancer cells 
(Mercer et al., 2004; Mercer & Mastro, 2005). Studies have demonstrated that
Cx43 expression in MDA-MB-231 results in decreased expression of OB-
cadherin (Li et al., 2008) and found a similar trend in Cx43 expressing MDA-
MB-435 cells. A significant decrease in N-cadherin, a protein which is involved 
in increased motility, invasion and metastases of breast cancer cells (Hazan et al., 
2000; Nieman et al., 1999)  seen in Cx43 over expressing MDA-MB-231 cells 
(Zhongyong et al., 2008) clearly show that it contributes to decreased metastasis 
in vivo. The anti metastatic effect of Cx43 may be related to enhanced sensitivity 
to apoptosis as Cx43 enhances apoptosis in response to chemotherapeutic agents 
or low serum in human glioblastoma cells (Huang et al., 2001). Studies have also 
demonstrated that Cx43 expression is directly correlated with the expression of 
BAK (Bcl-2 homologous antagonist/killer), a pro-apoptotic gene of the Bcl-2 
family, in human breast cancer tissue (Kanczuga-Koda et al., 2005). Cx43 
suppressed the cancer phenotype in human mammary carcinoma cell, MDA-MB-
435 and cell growth in culture and in animal models.
There remains little doubt that down regulation of Cx43 plays a very 
important role in the primary tumor formation and its metastasis in mammary 
glands. However the mechanism by which Cx43 down regulation occurs in breast 
cancer is far from clear. Several mechanisms like Cx43 promoter hyper-
methylation or a cancer-specific reduction of Cx43 expression /trafficking by the 
modulation of various components of the Cx43 life cycle appear to be involved in 
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the down regulation of connexins in mammary glands, but irreversible mutational 
alterations have not yet been proved to be among them.
CHAPTER 3
MATERIALS AND 
METHODS
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CHAPTER THREE
MATERIALS AND METHODS
3.1  MATERIALS 
3.1.1  CHEMICALS*
Chemical Name
Absolute ethanol
Acetic Acid 
Agarose            
Ammonium acetate
Betaine                                              
Bromophenol Blue         
Bovine Serum Albumin (BSA)                    
Chloroform         
Dimethyl sulfoxide (DMSO)                       
Dithiothritol (DTT)                                     
Ethidium Bromide
Ethylene diamine tetra acetate (EDTA)
Isoamyl alcohol
Isopropanol                                                 
Nitric acid                                                   
Phenol 
Pottassium bicarbonate 
Sodium acetate
Sodium bisulphite (Na2S2O3) 
Sodium chloride 
Sodium dodecyl sulphate 
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Sodium hydroxide
Silicon dioxide                                            
Sodium Iodide
Tris Base
3.1.2  ENZYMES
Taq Polymerase
Proteinase K
3.1.3  MISCELLANEOUS MATERIALS
1kbp DNA Ladder                                                 
dNTP mix            
*All the chemicals are of Standard Molecular Biology Grade.
3.1.4  REAGENTS
3.1.4.1  Reagents for DNA Extraction
Nuclear Lysis Buffer (NLB)
Ammonium acetate (4M)
EDTA (0.5M)
Proteinase K (20mg/ml)
2M Tris – HCl
70% Ethanol
Isopropanol
NaCl (5M)
SDS (10%)
3.1.4.2  Reagents for Agarose Gel Electrophoresis
1.5% Agarose
1X Tris Acetate EDTA (TAE) buffer (pH 8)
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Ethidium bromide 
3.1.4.3  Reagents for DNA Amplification
dNTP mix (dATP, dTTP, dGTP, dCTP in equal molar concentrations)
Primers
Taq polymerase
Taq Buffer (Tris-HCl, KCl, (NH4)2SO4, 1.5mM MgCl2) (pH 8.7)
3.1.4.4  Reagents for PCR product Purification
Low melting Agarose
Tris Acetate EDTA (TAE)
Sodium iodide solution (Sodium Iodide, sodium bisulphate)
Glass milk (Nitric acid treated Glass beads)
Wash buffer (Tris HCL pH 7.4 and Absolute Ethanol in 1:1 ratio)
3.1.4.5  Instruments
Centrifuge 5810R, Eppendorf, Germany
Table top centrifuge, Eppendorf, Germany
Deed freezer, LabTech Co. Ltd. Korea
Ice maker, LabTech Co. Ltd. Korea
Thermocycler, Applied Biosystems
Electrophoresis set, Wealter Corp, Taiwan.
Vortex-2 GENIE, Science Industries, Inc., USA
Ultraviolet Transilluminator, Bio Doc ITTM System, USA
Water bath, LabTech Co. Ltd. Korea.
Autoclave, Diahan Lab Tech Co. Ltd. Korea.
Measuring balance, Denver Instrument Company.
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3.1.4.6  Computer software used
ChromasMFC Version 2.22, Technelysium Pvt. Ltd., USA and ClustalX 
version 2.
3.2  METHODOLOGY
3.2.1  PATIENTS AND SAMPLES
Patients presenting for treatment of Breast cancer for the first time at the Sheri-I-
Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir 
between Jan 2008 to June 2010 were recruited for the study with prior informed 
consent. Patients underwent fine needle aspiration cytology and histopathological 
examination to establish the clinical profile. Out of the total 50 breast cancer 
cases under study, blood samples and surgically resected breast tissue (which 
included tumor tissue, normal tissue, and lymph node/s wherever involved) was
collected from 50 sporadic breast cancer cases. All samples were snap-frozen at –
80°C until analysis. A questionnaire was used to collect the information on 
Clinico-epidemiological characteristics such as age, family story of disease, body 
mass, menopause status, site of tumor, marital status, provisional diagnosis, 
lymph node/s involved and clinical tumor stage of patients.
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Clinico-
Epidemiological 
Features Patient Details
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13
Age 35 48 42 51 38 54 42 65 70 52 37 38 65
Sex1 F F F F F F F F F F F F F
Rural/Urban2 R R U U R R R R R R R R R
Breast   Involved3 R L R L L R L L R R L L L
Menopausal  Status4 Pre Post Pre Post Pre Post Pre Post Post Post Pre Pre Post
Provisional 
Diagnosis5
IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC
Lymph Node 
Status6
Y Y Y Y Y N Y Y Y N Y Y N
Clinical Tumor 
Stage7
IV IIa IIb IIb IIa IV IIIa IIIa IIIb IIIb IIa IIIb IIIa
                                                                                                                                                                                                                                                                
Clinico-
Epidemiological 
Features Patient Details
C14 C15 C16 C17 C18 C19 C20 C21 C22 C23 C24 C25 C26
Age 35 60 60 50 55 50 60 60 55 35 29 50 35
Sex1 F F F F F F F F F F F F
Rural/Urban2 R U U R U R R R R R R R U
Breast Involved3 R L R L L R L L L L L L R
Menopausal Status4 Pre Post Post Post Post Post Post Post Post Pre Pre Post Pre
Provisional 
Diagnosis5
IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC
Lymph Node 
Status6
Y N N Y Y Y Y N Y N Y Y N
Clinical Tumor 
Stage7
IV IIb IIb IIb IIIb IV IIIa IV IIb IIb IIIb IV IIa
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Clinico-
Epidemiological 
Features Patient Details
C27 C28 C29 C30 C31 C32 C33 C34 C35 C36 C37 C38 C39
Age 60 50 60 60 55 50 50 55 35 50 29 40 40
Sex1 F F F F F F F F F F F F F
Rural/Urban2 R R R R U R U R U R R R R
Breast Involved3 L R L R L R L L R L L L L
Menopausal Status4 Post Post Post Post Post Post Post Post Pre Post Pre Pre Pre
Provisional 
Diagnosis5
IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC
Lymph Node 
Status6
Y Y N N Y N Y Y Y Y Y Y Y
Clinical Tumor 
Stage7
IIa IIIa IIIb IIb IIa IV IIIa IIb IIIb IIb IIIb IV IV
Clinico-
Epidemiological 
Features Patient Details
C40 C41 C42 C43 C44 C45 C46 C47 C48 C49 C50
Age 38 37 52 70 65 42 54 38 51 40 48
Sex1 F F F F F F F F F F F
Rural/Urban2 R R R U R R R R R R R
Breast Involved3 L L L L R R L L R L L
Menopausal Status4 Pre Pre Post Post Post Pre Post Pre Post Pre Post
Provisional 
Diagnosis5
IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC IDC
Lymph Node
Status6
Y Y N N Y Y Y Y N Y Y
Clinical Tumor 
Stage7
IIa IIa IIb IIIa IIIa IIb IV IIIa IIIb IV IV
1Sex: M= male, F= female; 2Rural/Urban: Rural= R, Urban= U; 3Breast Involved: Right= R, Left= U; 4Menopausal Status: Pre= 
Premenopausal, Post= Postmenopausal; 5Provisional Diagnosis: IDC= Infiltrating Ductal Carcinoma, IBC= Inflammatory Breast 
Carcinoma, Pagt= Pagets disease; 6Lymph Node Status: Y= Yes, N= No; 7Clinical Tumor Stage: II(a,b)= When tumor size ranges 
from >2cm and >5cm and spreads to ipisilateral axillary nodes but no metastasis, III(a,b)= Tumor of nodes but no metastasis and 
IV: Tumor extends to chest wall, any number of nodes involved and metastasis.
Table 3.1: Clinico-epidemiological details of the study subjects.
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3.2.2  DNA EXTRACTION FROM TISSUE
1. Breast tissue (0.1g) was taken in a sterile petriplate and was finely 
chopped using sterile surgical blade.
2. Nuclear Lysis Buffer solution (3ml) was added to it and the mixture 
was transferred to sterile propylene tube, 200µl of SDS (10%) and 40µl 
of proteinase K (20 mg/ml) was added.
3. Mixture was incubated overnight at 45ºC in water bath.
4. 4ml of ammonium acetate (4M) and 3ml of chloroform was added and 
mixed gently followed by centrifugation at 3000rpm for 30 minutes at 
4ºC.
5. The supernatant obtained was transferred to a fresh sterile 50ml falcon 
tube and kept at -20ºC for 30 minutes. Isopropanol (5-10ml) was added 
along the sides of tube and mixed gently. White thread like precipitate 
of genomic DNA was seen. 
6. Precipitated DNA was retrieved carefully and washed 2-3 times with 
70% ethanol. The obtained DNA pellet was allowed to air dry at room 
temperature. 
7. The air dried pellet was dissolved in autoclaved MQ water or Tris –
HCl (pH=8) and incubated for 5 minutes at 65C, followed by storage 
at -20 C.
3.2.3  QUANTIFICATION
The absorbance of the DNA samples was recorded at 260nm on a double 
beam spectrophotometer and the concentration was determined by the 
following equation.
DNA (µg/ml) = A260×50×dilution factor.
The purity of DNA was established by using A260/A280 ratio.
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3.2.4  ANALYSIS OF DNA
The integrity of DNA isolated was assessed by agarose gel electrophoresis. 
Agarose gel was prepared by boiling agarose powder in 1X TAE buffer followed 
by cooling to 50-60°C. Ethidium bromide was added to a final concentration of 
0.5µg/ml. The gel solution was mixed by gentle swirling and was poured into an 
electrophoresis plastic tray (with sealed edges) with comb inserted. The gel was 
kept at room temperature for approximately 20 min to set into semisolid form.
3µl of DNA sample was mixed with 1µl of loading dye and loaded in to gel slots
along with molecular size marker in the last lane. Electrophoresis was carried out 
at 100 volts for 40 minutes. DNA band pattern was visualized and photographed. 
The samples showing bright, intact bands with no fragmentation or shearing 
and without any apparent contamination or streaking were chosen for further 
analysis.   
                     
3.2.5  AMPLIFICATION OF DIFFERENT EXONS OF BRCA2 
PCR amplification using 10 set of primers (Table 3.2) was done to amplify exon 
2, 9, 11.1, 11.2, 11.3, 11.4, 11.5, 18, 20 and 25 of BRCA2. PCR was carried out 
under conditions indicated for individual set of primers (Table 3.2). PCR assays 
were carried out in a reaction  volume of 50µl containing 100–200 ng of genomic 
DNA,0.2mM dNTPs (Sigma), 1X PCR buffer (Sigma), 0.5U of Taq DNA 
Polymerase (Sigma) and 10 pmol of each primer (Sigma). The PCR protocol and 
programme are given in Table 3.4 and 3.5 respectively.
3µl of PCR product was analyzed on 1.5% agarose gel by electrophoresis. 
The concentration of amplified PCR products was approximated by comparison 
with the intensity of the corresponding bands in the 1Kb DNA ladder.
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Amplicon
Primer Sequence (5' to 3')
Annealing
Temperature
Product size 
(bp)
Exon 2 F  CTC AGT CAC ATA ATA AGG AAT
R  ACA CTG TGA CGT ACT GGG TTT T
58 256
Exon 9 F CTA GTG ATT TTA AAC TAT AAT TTT G
R GTT CAA CTA AAC AGA GGA CT
53 164
Exon 11.1 F ATT TAG TGA ATG TGA TTG ATG G                                                                            
R TGA TTC TTT GCC TCT AGA AA
55 521
Exon 11.2 F CAA AAG TGG AAT ACA GTG ATA C                                                           
R TCT GTT TCA TGA AGT TCC TT
58 507
Exon 11.3 F TTC AAA AAT AAC TGT CAA TCC                                                                              
R TCT TTG AAG AAC ATT TTG CT
54 488
Exon 11.4 F ACA AAT GGG CAG GAC TCT TAG G
R TCT GCA TTC CTC AGA AGT GG
61 508
Exon 11.5 F GAA TCA GGA AGT CAG TTT GA
R TAT CAG TTG GCA TTT ATT ATT TTT
57 521
Exon 18 F GTG ACT TGT TTA AAC AGT GGA AR 
ATT GAG CAT CCT TAG TAA GCA
56 500
Exon 20 F AAG TGA ATA TTT TTA AGG CAG TT
R TAT ATG GTA AGT TTC AAG AAT
53 296
Exon 25 F TTA GAG TTT CCT TTC TTG CAT C
R AAG CTA TTT CCT TGA TAC TGG A
61 470
Table 3.2: Primers used for screening different exons of BRCA2.
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3.2.6  AMPLIFICATION OF CONNEXIN 43 
PCR primers were designed with mismatches to the pseudogene sequence to 
specifically amplify GJA1 and exclude any contribution from processed 
pseudogene (GJAIP) that has been identified in humans. The desired amplicons 
were obtained using Nested PCR method. In the first round, 1331bp product 
which contains the entire coding region plus a small portion of an intron at the 5’ 
UTR was amplified using primers “A”. In the second round, the generated 
amplicons were used as template to specifically amplify the N-terminal,         
mid-region and C-terminal region of Connexin 43 using respective primers
(Table 3.3). PCR assays were carried out in a reaction  volume of 50µl containing 
100–200 ng of genomic DNA, 0.2mM dNTPs (Sigma), 1X PCR buffer (Sigma),  
0.5 U of Taq DNA Polymerase (Sigma) and 10 pmol of each primer (Sigma). The 
Primer details, PCR protocol and programme are given in tables 3.3, 3.4 and 3.5.
3µl of PCR product was analyzed on 1.5% agarose gel by electrophoresis. 
The concentration of amplified PCR products was approximated by comparison 
with the intensity of the corresponding bands in the 1Kb DNA ladder.
Primer 
Name
Primer sequence (5' to 3') Annealing
Temperature
Product 
size (bp)
A F CGTGAAACCGTTGGTAGTA
R GCACTTTCTACAGCACCTT
54 ̊C 1331
B F CGTGAAACCGTTGGTAGTA
R CCCCTCGCATTTTCACCTTACC
62 ̊C 552
C F TTTGAGGTGGCCTTCTTGCTGA
A TAGGCGAGAGGGGAGCGGT
63 ̊C 350
D F TGGGTACAAGCTGGTTACTG
R GCACTTTCTACAGCACCTT
58 ̊C 365
Table 3.3: Primers used for screening Connexin 43.
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Table 3.4: PCR protocol
STEP TEMPERATURE °C TIME
Initial Denaturation 95 6 min
Denaturation 95 30 sec
35 CyclesAnnealing X 45 sec
Extension 72 1 min
Final Extension 72 10 min
Table3.5: PCR cycling parameters
REAGENT VOLUME
REQUIRED
FINAL CONCENTRATION
Taq Buffer (10X) 5.0 µl 1 X
dNTP mix (2mM) 5.0 µl 0.2mM
Forward Primer 
(10pmoles/µl)
1.0 µl 0.2pmole/µl
Reverse Primer 
(10pmoles/µl)
1.0 µl 0.2pmole/µl
Taq DNA Polymerase 
(5U/µl)
0.1 µl 0.01 units/ µl
Genomic DNA 2.0 µl
MilliQ  water 35.9 µl
Total  volume 50 µl
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3.2.7  PURIFICATION OF THE PCR PRODUCTS
Prior to sequencing every PCR product was purified (Vogelstein and Gillespie 
1976) as follows:
1. PCR product was loaded on a 1.5% agarose gel and the electrophoresis 
was carried out at 100 volts until the dye had migrated for a sufficient 
distance through the gel.
2. The band of interest was cut using a sharp clean surgical blade/scalpel.
3. Each excised gel piece was dispensed in approx. 3 times sodium iodide 
and the tubes were incubated in a water bath at 45°C-55°C for 5 
minutes or till the gel melts completely. The tubes were gently shaken 
during this process.
4. 10-15 µl of glass milk was added to each tube and incubated on ice for 
15 min, vortexing slightly 2-3 times during incubation. 
5. The tubes were centrifuged in a microfuge at maximum speed for 90 
sec and the supernatant discarded.
6. Wash buffer (500µl) of wash buffer was added to the glass milk pellet 
to resuspend it into it completely by vortexing, followed by 
centrifugation at 14,000 rpm.
7. Washing was repeated twice. 
8. Pellet was allowed to air dry and 10-15µl of MilliQ water was added, 
as per the volume of the glass-milk added at step 4.
9. Tubes were incubated in a water bath at 45-55°C for 5 minutes and 
then centrifuged at maximum speed for 45 minutes.
10. The supernatant (purified DNA fragment) was aspirated out carefully 
without disturbing the pellet and stored in the fresh eppendorf tubes.
11. The quality and the concentration of the purified DNA fragment was 
checked on 1.5% agarose gel.
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3.2.8  DNA SEQUENCING
Sequencing was done commercially using the services of The Centre for 
Genomic Applications (TCGA), Delhi. DNA sequences of the amplicons were 
obtained in fasta and pdf formats. For analyzing the sequencing data in fasta 
format, software programs ClustalX version 2 (for sequence alignment) 
(Larkin et al., 2007; Thompson et al., 1997) and Chromas Pro Version 1.49 
beta 2 (for detailed inspection of the individual chromatograms), were used. 
The pdf file of each DNA sequence was used for visual inspection of the 
sequencing chromatogram using Acrobat Reader 8.0.
3.2.9  STATISTICAL ANALYSIS
All statistical analysis was performed using SPSS program. Odds ratio was 
performed to determine the association of presence of mutations with various 
Clinico-epidemiological characteristic such as age, menopause status, site of 
tumor, provisional diagnosis, lymph node/s involved and clinical stage of tumor. 
Statistical significance was considered when p ≤ 0.05. The prevalence of    
BRCA2 mutations obtained in Kashmiri patients was compared                       
with compiled data reported for breast cancer in BIC database 
(www.ngri.nih.gov/intramuraresearch/BIC) and other areas including India.
CHAPTER 4
RESULTS
Results
4.1  GENOMIC DNA INTEGRITY
Genomic DNA isol
concentration and purification by agarose
Concentration of the samples ranged
amplification. The purity 
1.60-1.92 in all DNA preparations. Gel
DNA in nearly all sample
molecular weight more than 23kb is considered to be fairly intact and appropriate for 
PCR.
Fig. 4.1: Genomic DNA extracted from blood 
M shows marker (Hind III digested λ DNA) and lanes 1
Lane 1 shows  separation pattern of Hind III digested λ DNA and sample DNA was run in the 
remaining lanes.
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ated from tissue samples was assessed for its integrity, 
gel electrophoresis and spectrophotometry.
between 200ng/µl to 800ng/µl, adequate for 
determined by OD260/OD280 ratio was in the range of 
analysis indicated high molecular weight 
s, with some showing slight degradation. DNA having 
samples run on 0.8% agarose gel. (a) Lane represented by 
-10 show analysis of genomic DNA
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4.2  BRCA2 ANALYSIS
4.2.1  PCR AMPLIFICATION OF BRCA2
Ten set of primers (Table 
(11.1, 11.2, 11.3, 11.4, 11.5), 
strictly in accordance with conditions 
analyzed on the 1% agarose gel. After visualizing under UV light, it was seen that all 
the exons were successfully amplified from DNA samples, generating specific PCR 
products strictly as per the expected sizes a
sequenced. Prior to sequencing, the final concentration of amplicons was adjusted to 
50ng/µl.
                  1   2   3   4   5   6   7   8   
     
                         
               
Fig. 4.2a: Exon 2 amplification product (256bp). PCR products generated from various samples run on 
1.5% agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separat
ladder, 2-20 show analysis of 5µl aliquot of PCR product.
3.2) were used to amplify exon 2, exon 9, 
exon 18, exon 20 and exon 25 of BRCA2  respectively
described in methods. PCR product (
nd were sufficient to be purified and 
9   10   11   12   13   14   15   16   17   18   19    
ion pattern of 1 kb 
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exon 11 
5µl) was 
20
256bp
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Fig. 4.2b: Exon 9 amplification product (164bp). PCR products generated from various samples run on 
1.5% agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separat
ladder, 2-20 show analysis of 5µl aliquot of PCR product.
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Fig. 4.2c: Exon 11.1 fragment amplification product (521bp). PCR products generated from various 
samples run on 1.5% agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separati
pattern of 1 kb ladder, 2
                        1   2   3   4   5   6   7   8   9   10   11   12 
             
               
                      
Fig. 4.2d: Exon 11.2 fragment amplification product (507bp). PCR products generated from various 
samples run on 1.5% agarose
pattern of 1 kb ladder, 2
19  
ion pattern of 1 kb 
19 
-20 show analysis of 5µl aliquot of PCR product.
  13   14   15   16   17   18  19  
gel with 1 kb DNA ladder marker. Lane 1 shows the separation 
-20 show analysis of 5µl aliquot of PCR product.
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Fig. 4.2e: Exon 11.3 fragment amplification product (488bp). PCR products generated from various 
samples run on 1.5% agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separat
pattern of 1 kb ladder, 2
                       1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   
          
         
Fig. 4.2f: Exon 11.4 fragment amplification product (508bp). PCR products generated from various 
samples run on 1.5% agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separat
pattern of 1 kb ladder, 2
                        1   2   3   4   5   6   7   8   9   10   11   12 
               
Fig. 4.2g: Exon 11.5 fragment amplification product (521bp). PCR products generated from various 
samples run on 1.5% 
pattern of 1 kb ladder, 2
1
-20 show analysis of 5µl aliquot of PCR product.
19  
-20 show analysis of 5µl aliquot of PCR product.
  13   14   15   16   17   18  19  
agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separat
-20 show analysis of 5µl aliquot of PCR product.
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Fig. 4.2h: Exon 18 amplification product (500bp). PCR products generated from various samples run on 
1.5% agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separat
ladder, 2-12 show analysis of 5µl aliquot of PCR product.
        1    2   3    4    5  
          
Fig. 4.2i: Exon 20 amplification product (296 
1.5% agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separat
ladder, 2-20 show analysis of 5µl aliquot of PCR product
          1    2   3    4    5  
         
              
Fig. 4.2j: Exon 25 amplification product (470bp). PCR products generated from various samples run on 
1.5% agarose gel with 1 kb DNA ladder marker. Lane 1 shows the separat
ladder, 2-20 show analysis of 5µl aliquot of PCR product.
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ion pattern of 1 kb 
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bp). PCR products generated from various samples run on 
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4.2.2  SEQUENCE ANALYSIS
The sequencing data was obtained commercially from the Center for 
Genomics Application, New Delhi. DNA sequences of the amplicons wee obtained 
in fasta and pdf formats. The fasta files were analyzed using ClustalX software for 
sequence alignment and by Chromas Pro software for the detailed inspection of the 
chromatograms individually. The pdf file of each DNA sequence was used for visual 
inspection of the entire sequencing chromatograms.
Mutational screening of commonly mutated exons (2, 9, 11, 18, 20, 25) of 
BRCA2 in 50 sporadic tumor samples of breast cancer patients from Kashmir 
revealed a total of five variations, out of which four were somatic and one was 
germline in nature. The germline nature of the variation was established as the 
variation observed in tumor was also identified in its adjacent normal tissue, blood 
and lymph node of the same patient. All somatic variations were located in exon 11 
of BRCA2, and the germline variation was observed in UTR region of exon 2 
screened. Mutation pattern of BRCA2 revealed only missense mutations and no 
insertion or any kind of deletion was seen in any of the samples. Four mutations 
observed in exon eleven are G:C > A:T transition at position 846 and 868 and A:T > 
G:C transitions at codon positions 991 and 1131 (Table 4.1). Codons coding for amino-
acid positions at 846 and 868 were seen to be present in heterozygous state in normal breast 
tissue samples whereas this heterozygous nature of both the codons was seen to be lost in 
associated tumor samples in 44 out of 50 patients (88%). It was also seen that the loss of 
heterozygosity at theses two codon positions was always associated and none of the 
two was individually lost in any of the samples. C > A transition at amino-acid 
position 846 is a silent mutation whereas the C > A transition at 868 amino-acid 
position is a mis-sense mutation leading to the replacement of proline by threonine. 
Mutation at amino-acid position 991 leading to replacement of aspargine by aspartic 
acid was present in 24% (12/50) of all cancer cases whereas the A to C transition at 
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amino-acid position 1131 was a silent mutation and was found in 20% (10/50) of all 
cancer patients. The germline variation A:T > G:C transition observed in UTR region 
of exon 2 at contig position 13870572 was observed in 32% (16/50) of all patients. C to 
A transition at amino-acid position 868 is novel whereas others variations have 
already been reported. However no mutation of any kind either germ-line or somatic was 
observed in other four exons screened i.e., exon 9, 18, 20 and 25. 
Exon Codon   
Position
rs no Observed base   
pair change
Amino acid 
change
Chromatogram
   2    5’ UTR 1799943       A to G      NIL
  11        846 11571654       C to A      NIL
   
   11       868    Novel       C to A Thr to Pro
   11       991 1799944      A to G      NIL
   11      1131 1801406       A to G      NIL
Table 4.1: Mutations found in different exons of Brca2 in ethnic Kashmiri population.
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a)    Tumor (Sample No 14)
      
b) Normal (Using Forward Primer)
  
                                                           
c) (Confirmed by Reverse Primer)
Figure 4.3a:  Partial chromatograms representing the normal and mutant (Shown by arrows) profile in  Exon 
11 of two linked mutations (C>A) at codon position 846 and 868 a) Tumor b) Normal (forward 
primer) c) SNPs confirmed by reverse primer
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a) Tumor    (Using Forward Primer)                                  b)        (Confirmed by Reverse Primer)
                                                
b) Normal (Sample no 12)
Figure 4.3b:  Partial chromatograms representing the normal and mutant (Shown by arrows) profile in Exon 
11 at codon position 991 (A>G) a) Tumor (Forward primer) b) SNP confirmed by reverse primer 
c) Normal. 
       
a) Tumor  (Using Forward Primer)    b)     (Confirmed by Reverse Primer)
                           
                                                            
c) Normal (Sample no 14)
Figure 4.3c:  Partial chromatograms representing the normal and mutant (Shown by arrows): profile in (1) 
Exon 11 at codon position 1131 a) Tumor (forward primer) b) SNP confirmed by reverse primer 
c) Normal.
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a) Tumor                                                                      b)      Normal (Sample no 2)
Figure 4.3d:  Partial chromatograms representing the normal and mutant (Shown by arrows): profile in (1)   
Exon 2 in the UTR region at Contig position 13870572 a) Tumor b) Normal.
RVASPSRKVQ  FNQNTNLRVI  QKNQEETPSI  SKITVNPDSE     ELFSDNENNF VFQVANERNN
LALGNTKELH   ETDLTCVNEP  IFKNSTMVLY  GDTGDKQATQ  VSIKKDLVYV   LAEENKNSVK
QHIKMTLGQD LKSDISLNID   KIPEKNNDYM  NKWAGLLGPI   SNHSFGGSFR TASNKEIKLS
EHNIKKSKMF  FKDIEEQYPTSL
Normal translation of BRCA2 gene
RVASPSRKVQ  FNQNTNLRVI  QKNQEETTSI SKITVNPDSE     ELFSDNENNF VFQVANERNN
LALGNTKELH   ETDLTCVNEP  IFKNSTMVLY  GDTGDKQATQ  VSIKKDLVYV   LAEENKNSVK
QHIKMTLGQD LKSDISLNID   KIPEKNNDYM  DKWAGLLGPI   SNHSFGGSFR TASNKEIKLS
EHNIKKSKMF  FKDIEEQYPTSL
Translation of BRCA2 gene (Affected): Showing codon 846 (Silent mutation), codon 
868 pro to thr (red in normal, green in affected), codon 991 asn to asp (red in normal, 
orange in affected), codon 1131 (silent mutation).
Table 4.2: Translation of normal and affected BRCA2 gene exon 11.
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Patient 
ID
Age Rural/
Urban
Menopausal
Stage
Provisional
Diagnosis
Lymph 
node/s
Clinical
Tumor
Stage
Codon
No
Base 
change
Mutation 
(cDNA 
sequence)
Amino-acid
change
C1 35 R Pre IDC Y IV 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C2 48 R Post IDC Y IIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C4 51 U Post IDC Y IIb 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C5 38 U Pre IDC Y IIa
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C6 54 R Post IDC N IV 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C7 42 R Pre IDC Y IIIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C8 65 R Post IDC Y IIIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C9 70 R Post IDC Y IIIb
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C10 52 R Post IDC N IIIb 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C11 37 R Pre IDC Y IIa
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C12 38 R Pre IDC Y IIIb
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
C13 65 R Post IDC N IIIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C14 35 R Pre IDC Y IVa
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C15 60 U Post IDC N IIb 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C17 60 R Post IDC Y IIb
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C18 50 U Post IDC Y IIIb
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C19 50 R Post IDC Y IV
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C20 60 R Post IDC Y IIIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C21 60 R Post IDC N IV
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C23 35 R Pre IDC N IIb 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C24 29 R Pre IDC Y IIIb
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C25 50 R Post IDC Y IV
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C26 35 U Pre IDC N IIa
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C27 60 R Post IDC Y IIa
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C28 50 R Post IDC Y IIIa 846 TCC>TCA 2538C>A
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Table 4.3: Clinico-epidemiological details and nature of BRCA2 mutations in sporadic breast cancer 
patients from Kashmir valley.
868 CCT>ACT 2602C>A Pro>Thr
C29 60 R Post IDC N IIIb 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C31 55 R Post IDC Y IIa
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C32 50 R Post IDC N IV
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C33 50 U Post IDC Y IIIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C34 55 R Post IDC Y IIb
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C35 35 U Pre IDC Y IIIb
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C36 50 R Post IDC Y IIb 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C37 29 R Pre IDC Y IIIb
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C38 40 R Pre IDC Y IV
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C39 40 R Pre IDC Y IV 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C41 37 R Pre IDC Y IIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C42 52 R Post IDC N IIb 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C43 70 U Post IDC N IIIa
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C44 65 R Post IDC Y IIIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C46 54 R Post IDC Y IV
846
868
991
TCC>TCA
CCT>ACT
AAC>GAC
2538C>A
2602C>A
2971A>G
Pro>Thr
Asn>Asp
C47 38 R Pre IDC Y IIIa 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C48 51 R Post IDC N IIIb 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
C49 40 R Pre IDC Y IV
846
868
1131
TCC>TCA
CCT>ACT
AAA>AAG
2538C>A
2602C>A
3393A>G
Pro>Thr
C50 48 R Post IDC Y IV 846
868
TCC>TCA
CCT>ACT
2538C>A
2602C>A Pro>Thr
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4.2.3  BRCA2 MUTATIONS AND CLINICO-EPIDEMIOLGICAL 
FEATURES 
The presence of BRCA2 mutations when compared with various clinico-
epidemiological attributes of sporadic breast cancer patients showed some 
association though statistically not significant, with early onset and late onset breast 
cancer cases, menopausal stage and advanced clinical stage (III and IV) of the 
disease (Table 4.4a & Table 4.4b). However there was no association seen with
positive lymph node status and breast involved.
Table 4.4a: Association of two associated mutations at codon position 846 (rs11571654) and 868 
(Novel) on exon 11 of BRCA2 with Clinico-epidemiological features of sporadic 
breast cancer patients of Kashmir (n=50).
    
Features
Codon position 
846 and 868 P-value Odds Ratio
Age
≤ 45 years
≥ 45 years
16/20
28/30 
0.65 1.38
(0.1-17.67)
Rural
Urban
36/40
8/10 0.5
0.44
(0.032-6.18)
Menopause Status
Pre-menopausal
Post-menopausal
16/20
28/30
0.65 1.38
(0.1-17.67)
Breast Involved
Right
Left
14/16
30/34
0.69 1.4
Provisional Diagnosis
IDC
IBC
Paget’s Disease
44/50
0/0
0/0
N/A
Lymph Nodes Involved
Yes
No
32/36
12/14
0.64 0.75
(0.05-9.8)
Tumor Details
Clinical Tumor Stage
II (a,b)
III (a,b)
IV
14/20
18/18
12/12
0.54
0.3
0.48
0.5 (0.03-6.6)
4 (0.27-58.56)
2 (0.2-19.9)
Results
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Features Codon position 
991
P-value Odds Ratio
Age
≤ 45 years
≥ 45 years
6/20
6/30
0.46 1.7
(0.1-4.7)
Rural
Urban
10/40
2/10 0.65
0.75
(0.06-8.38)
Menopause Status
Pre-menopausal
Post-menopausal
6/20
6/30
0.46 1.7
(0.26-10.92)
Breast Involved
Right
Left
4/16
8/34
0.65 1.08
(0.15-7.64)
Provisional Diagnosis
IDC
IBC
Paget’s Disease
10/50
0/0
0/0
N/A N/A
Lymph Nodes Involved
Yes
No
10/36
2/14
0.44 0.43
(0.04-4.5)
Tumor Details
Clinical Tumor Stage
II (a,b)
III (a,b)
IV
4/20
4/18
4/12
0.66
0.53
0.48
1.14(0.12-10.38)
1.75(0.17-17.68)
2 (0.2-19.9)
Table 4.4b:  Association of mutation at codon position 991 (rs1799944) on exon 11 of BRCA2 
with Clinico-epidemiological features of sporadic breast cancer patients of 
Kashmir (n=50).
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Figure 4.4a: Representative sequencing chromatogram showing the mutant and normal profile (shown 
by black arrows) in Exon 2 of BRCA2 gene of a) Tumor sample b) Normal sample along 
with its NCBI fasta sequence.
  a)
b)
CTCAGTCACATAATAAGGAATGCATCCCTGTGTAAGTGCATTTTGGTCTTCTGTTTTGCAGACTTATTTACCAA
ACATTGGAGGAATATCGTAGGTAAAAATGCCTATTGGATCCAAAGAGAGGCCAACATTTTTTGAAATTTTTAA
GACACGCTGCAACAAAGCAGGTATTGACAAATTTTATATAACTTTATAAATTACACCGAGAAAGTGTTTTCTA
AAAAATGCTTGCTAAAAACCCAGTACG
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Figure 4.4b: Multiple sequence alignment of samples generated from Exon 2 amplification of 
BRCA2. The fasta  sequences of samples were aligned with the reference sequence 
available from NCBI website (blue higlight), in addition to the sequence of a normal 
DNA samples (pointed out by red arrows), using Clustal X software. White arrow shows 
the nucleotide position where single base pair change was observed.
Results
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   a)
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Figure 4.4c: Representative sequencing chromatogram of 11.1 fragment of exon 11 (BRCA2) of            
a) Tumor sample b) Normal sample along with its NCBI fasta sequence.
b)
TTTAGTGAATGTGATTGATGGTACTTTAATTTTGTCACTTTGTGTTTTTATGTTTAGGTTTATTGCATTC
TTCTGTGAAAAGAAGCTGTTCACAGAATGATTCTGAAGAACCAACTTTGTCCTTAACTAGCTCTTTTGGG
ACAATTCTGAGGAAATGTTCTAGAAATGAAACATGTTCTAATAATACAGTAATCTCTCAGGATCTTGATT
ATAAAGAAGCAAAATGTAATAAGGAAAAACTACAGTTATTTATTACCCCAGAAGCTGATTCTCTGTCATG
CCTGCAGGAAGGACAGTGTGAAAATGATCCAAAAAGCAAAAAAGTTTCAGATATAAAAGAAGAGGTCTT
GGCTGCAGCATGTCACCCAGTACAACATTCAAAAGTGGAATACAGTGATACTGACTTTCAATCCCAGAAA
AGTCTTTTATATGATCATGAAAATGCCAGCACTCTTATTTTAACTCCTACTTCCAAGGATGTTCTGTCAA
ACCTAGTCATGATTTCTAGAGGCAAAGAATCA
Results
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a)
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Figure 4.4d: Representative sequencing chromatogram showing the normal and mutant profile 
(shown by black arrows) in 11.2 fragment of exon 11 (BRCA2) of a) Tumor sample   
b) Normal sample along with its NCBI fasta sequence.
b)
CAAAAGTGGAATACAGTGATACTGACTTTCAATCCCAGAAAAGTCTTTTATATGATCATGAAAATGCCAGCACT
CTTATTTTAACTCCTACTTCCAAGGATGTTCTGTCAAACCTAGTCATGATTTCTAGAGGCAAAGAATCATACAA
AATGTCAGACAAGCTCAAAGGTAACAATTATGAATCTGATGTTGAATTAACCAAAAATATTCCCATGGAAAAGA
ATCAAGATGTATGTGCTTTAAATGAAAATTATAAAAACGTTGAGCTGTTGCCACCTGAAAAATACATGAGAGTA
GCATCACCTTCAAGAAAGGTACAATTCAACCAAAACACAAATCTAAGAGTAATCCAAAAAAATCAAGAAGAAAC
TACTTCAATTTCAAAAATAACTGTCAATCCAGACTCTGAAGAACTTTTCTCAGACAATGAGAATAATTTTGTCT
TCCAAGTAGCTAATGAAAGGAATAATCTTGCTTTAGGAAATACTAAGGAACTTCATGAAACAGA
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Figure 4.4e: Multiple sequence alignment of samples generated from 11.2 fragment amplification of 
exon 11 (BRCA2). The fasta  sequences of samples were aligned with the reference 
sequence available from NCBI website (blue higlight), in addition to the sequence of a 
normal DNA samples (pointed out by red arrows), using Clustal X software. White arrow 
shows the nucleotide position where single base pair change was observed.
Results
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  a)
Results
106
Figure 4.4f: Representative sequencing chromatogram showing the normal and mutant profile (shown 
by black arrows) in 11.3 fragment of exon 11 (BRCA2) of  a) Tumor sample b) Normal 
sample along with its NCBI fasta sequence.
  b)
TTCAAAAATAACTGTCAATCCAGACTCTGAAGAACTTTTCTCAGACAATGAGAATAATTTTGTCTTCCAAGTA
GCTAATGAAAGGAATAATCTTGCTTTAGGAAATACTAAGGAACTTCATGAAACAGACTTGACTTGTGTAAACG
AACCCATTTTCAAGAACTCTACCATGGTTTTATATGGAGACACAGGTGATAAACAAGCAACCCAAGTGTCAAT
TAAAAAAGATTTGGTTTATGTTCTTGCAGAGGAGAACAAAAATAGTGTAAAGCAGCATATAAAAATGACTCT
AGGTCAAGATTTAAAATCGGACATCTCCTTGAATATAGATAAAATACCAGAAAAAAATAATGATTACATGAAC
AAATGGGCAGGACTCTTAGGTCCAATTTCAAATCACAGTTTTGGAGGTAGCTTCAGAACAGCTTCAAATAAGG
AAATCAAGCTCTCTGAACATAACATTAAGAAGAGCAAAATGTTCTTCAAAG
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Figure 4.4g: Multiple sequence alignment of samples generated from 11.3 fragment amplification of 
Exon 11 (BRCA2). The fasta  sequences of samples were aligned with the reference 
sequence available from NCBI website (blue higlight), in addition to the sequence of a 
normal DNA samples (pointed out by red arrows), using Clustal X software. White 
arrow shows the nucleotide position where single base pair change was observed.
Results
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  a)
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Figure 4.4h: Representative sequencing chromatogram showing the normal and mutant profile (shown 
by black arrows)  in 11.4 fragment of exon 11 (BRCA2) a) Tumor sample b) Normal 
sample along with its NCBI fasta sequence.
ACAAATGGGCAGGACTCTTAGGTCCAATTTCAAATCACAGTTTTGGAGGTAGCTTCAGAACAGCTTCAAATAA
GGAAATCAAGCTCTCTGAACATAACATTAAGAAGAGCAAAATGTTCTTCAAAGATATTGAAGAACAATATCCT
ACTAGTTTAGCTTGTGTTGAAATTGTAAATACCTTGGCATTAGATAATCAAAAGAAACTGAGCAAGCCTCAGT
CAATTAATACTGTATCTGCACATTTACAGAGTAGTGTAGTTGTTTCTGATTGTAAAAATAGTCATATAACCCC
TCAGATGTTATTTTCCAAGCAGGATTTTAATTCAAACCATAATTTAACACCTAGCCAAAAGGCAGAAATTACA
GAACTTTCTACTATATTAGAAGAATCAGGAAGTCAGTTTGAATTTACTCAGTTTAGAAAACCAAGCTACATAT
TGCAGAAGAGTACATTTGAAGTGCCTGAAAACCAGATGACTATCTTAAAGACCACTTCTGAGGAATGCAGA
Results
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Figure 4.4i: Multiple sequence alignment of amplified samples generated from 11.4 fragment of Exon 
11 (BRCA2). The fasta  sequences of samples were aligned with the reference sequence 
available from NCBI website (blue higlight), in addition to the sequence of a normal DNA 
samples (pointed out by red arrows), using Clustal X software. White arrow shows the 
nucleotide position where single base pair change was observed.
Results
111
  a)
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Figure 4.4j: Representative sequencing chromatogram of 11.5 fragment of exon 11 (BRCA2) a) Tumor 
sample b) Normal sample along with its NCBI fasta sequence.
  b)
GAATCAGGAAGTCAGTTTGAATTTACTCAGTTTAGAAAACCAAGCTACATATTGCAGAAGAGTACATTTGAAG
TGCCTGAAAACCAGATGACTATCTTAAAGACCACTTCTGAGGAATGCAGAGATGCTGATCTTCATGTCATAAT
GAATGCCCCATCGATTGGTCAGGTAGACAGCAGCAAGCAATTTGAAGGTACAGTTGAAATTAAACGGAAGTTT
GCTGGCCTGTTGAAAAATGACTGTAACAAAAGTGCTTCTGGTTATTTAACAGATGAAAATGAAGTGGGGTTTA
GGGGCTTTTATTCTGCTCATGGCACAAAACTGAATGTTTCTACTGAAGCTCTGCAAAAAGCTGTGAAACTGTT
TAGTGATATTGAGAATATTAGTGAGGAAACTTCTGCAGAGGTACATCCAATAAGTTTATCTTCAAGTAAATGT
CATGATTCTGTTGTTTCAATGTTTAAGATAGAAAATCATAATGATAAAACTGTAAGTGAAAAAAATAATAAA
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Figure 4.4k: Representative sequencing chromatogram of Exon 9 of BRCA2 gene a) Tumor sample    
b) Normal sample along with its NCBI fasta sequence.
  a)
  b)
CTAGTGATTTTAAACTATAATTTTTGCAGAATGTGAAAAGCTATTTTTCCAATCATGATGAAAGTCTGAAGA
AAAATGATAGATTTATCGCTTCTGTGACAGACAGTGAAAACACAAATCAAAGAGAAGCTGCAAGTCATGGTA
AGTCCTCTGTTTAGTTGAAC
Results
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  a)
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Figure 4.4l: Representative sequencing chromatogram of Exon 18 of BRCA2 gene a) Tumor sample 
b) Normal sample along with its NCBI fasta sequence.
  b)
GTGACTTGTTTAAACAGTGGAATTCTAGAGTCACACTTCCTAAAATATGCATTTTTGTTTTCACTTTTAGAT
ATGATACGGAAATTGATAGAAGCAGAAGATCGGCTATAAAAAAGATAATGGAAAGGGATGACACAGCTGCA
AAAACACTTGTTCTCTGTGTTTCTGACATAATTTCATTGAGCGCAAATATATCTGAAACTTCTAGCAATAAA
ACTAGTAGTGCAGATACCCAAAAAGTGGCCATTATTGAACTTACAGATGGGTGGTATGCTGTTAAGGCCCAG
TTAGATCCTCCCCTCTTAGCTGTCTTAAAGAATGGCAGACTGACAGTTGGTCAGAAGATTATTCTTCATGGA
GCAGAACTGGTGGGCTCTCCTGATGCCTGTACACCTCTTGAAGCCCCAGAATCTCTTATGTTAAAGGTAAATT
AATTTGCACTCTTGGTAAAAATCAGTCATTGATTCAGTTAAATTCTAGAAGTTTTACATTTAAATTTTAAAT
GCTTACTAAGGATGCTCAAT
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Figure 4.4m: Representative sequencing chromatogram of Exon 20 of BRCA2 gene a) Tumor sample 
b) Normal sample along with its NCBI fasta sequence.
  a)
  b)
AAGTGAATATTTTTAAGGCAGTTCTAGAAGAATGAAAACTCTTATGATATCTGTAATAGAATTGAATACATATTTAACTA
CTAAATCAATATATTTATTAATTTGTCCAGCTTGAAACTTACCATATATTTCTTTCTTTTGATACAATTAATTTGTTTGTTTG
TTTGAGATGGAGTTTCGGTCTCTTGCCCAGGCTGGAGTGCAATGCGTGATCTTGGTTCACTGCAGCCTCCACCTCCCGGG
TTCAAGTGATTCTCCTGC
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Figure 4.4n: Representative sequencing chromatogram of Exon 25 of BRCA2 gene a) Tumor sample 
b) Normal sample along with its NCBI fasta sequence.
  a)
  b)
TTAGAGTTTCCTTTCTTGCATCTTAAAATTCATCTAACACATCTATAATAACATTCTTTTCTTTTTTTTCCATTCTAGGACTTG
CCCCTTTCGTCTATTTGTCAGACGAATGTTACAATTTACTGGCAATAAAGTTTTGGATAGACCTTAATGAGGACATTATTA
AGCCTCATATGTTAATTGCTGCAAGCAACCTCCAGTGGCGACCAGAATCCAAATCAGGCCTTCTTACTTTATTTGCTGGAG
ATTTTTCTGTGTTTTCTGCTAGTCCAAAAGAGGGCCACTTTCAAGAGACATTCAACAAAATGAAAAATACTGTTGAGGTA
AGGTTACTTTTCAGCTCACCACACATTTTGGTATTTTTCTATTTTGACAGTCCAGTATCAAGGAAATAGCTT
Results
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4.3  CONNEXIN 43 ANALYSIS
4.3.1  AMPLIFICATION OF CONNEXIN 43
Four sets of primers were used to amplify coding region of Connexin 43 using 
Nested PCR method. In the first round, 1331bp product which contains the entire 
coding region plus a small portion of an intron at the 5’ UTR was amplified using set 
‘A’. In the second round, the generated amplicons were used as template to 
specifically amplify the N-terminal, mid-region and C-terminal region of Connexin 
43 using primer sets ‘B’, ‘C’ and ‘D’ strictly in accordance with the conditions 
described in methods (Table 3.3). PCR product (5µl) was analyzed on the 1% 
agarose gel. After visualizing under UV light, it was seen that the amplicons were 
successfully amplified from DNA samples, generating specific PCR products strictly 
as per the expected size and were sufficient to be purified and sequenced. Prior to 
sequencing, the final concentration of amplicons was adjusted to 50ng/µl.
                                    1                         2         3          4            5            6           7         
                                1331bp
Fig 4.5a: Amplification product of entire coding region of Cx 43 along with small portion of UTR (1331bp). 
PCR products generated from various samples run on 1.5% agarose gel with 1 kb DNA ladder 
marker. Lane 1 shows the separation pattern of 1 kb ladder, 2-7 show analysis of 5µl aliquot of 
PCR product.
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Fig 4.5b: Amplification product of N
various samples run on 1.5% agarose gel 
separation pattern of 1 kb ladder, 2
                            1     2 
                        
                            
Fig 4.5c: Amplification product of 
samples run on 1.5% agarose gel with
pattern of 1 kb ladder, 2
                       1     
                           
                           
Fig 4.5d: Amplification product of 
various samples run on 1.5% agarose gel with 1 kb DNA ladder marker. a)
separation pattern of 1 kb ladder, 2
2   3     4       5       6       7      8        9     10   
-terminal region of Cx43 (552bp). PCR products generated from 
with 1 kb DNA ladder marker. Lane 1 shows the 
-10 show analysis of 5µl aliquot of PCR product.
  3     4       5       6       7      8        9     10   11
mid-region of Cx43 (350bp). PCR products generated from various 
1 kb DNA ladder marker. a) Lane 1 shows the separation 
-11 show analysis of 5µl aliquot of PCR product.
    2       3        4          5          6          7       8
C-terminal region of Cx43 (365bp). PCR products generated from 
Lane 1 shows the 
-8 show analysis of 5µl aliquot of PCR product
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552bp
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.
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4.3  SEQUENCE ANALYSIS
The sequencing data was obtained commercially from the Center for Genomics 
Application, New Delhi. DNA sequences of the amplicons were obtained in fasta 
and pdf formats. The fasta files were analyzed using ClustalX software for sequence 
alignment and by Chromas Pro software for the detailed inspection of the 
chromatograms individually. The pdf file of each DNA sequence was used for visual 
inspection of the entire sequencing chromatograms.
Sequence analysis (which included thorough analysis of the chromatograms 
and multiple sequence alignments) of all the three fragments of Connexin 43 gene in 
50 sporadic tumor samples of breast cancer patients from Kashmir did not reveal any 
kind of variation with respect to standard Connexin 43 sequence available in NCBI 
database in any of the samples screened.
Results
Figure 4.6a: Multiple sequence align
Cx43. The fasta  sequences of samples were aligned with the reference sequence available 
from NCBI website (blue higlight), in 
(pointed out by arrow head), using Clustal X software.
ment of samples generated from N-terminal region amplification
addition to the sequence of a normal DNA samples 
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of 
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Figure 4.6b: Multiple sequence alignment of samples generated from mid-region amplification of Cx43. 
The fasta  sequences of samples were aligned with the reference sequence available from 
NCBI website (blue higlight), in addition to the sequence of a normal DNA samples 
(pointed out by arrow head), using Clustal X software.
Results
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Figure 4.6c: Multiple sequence alignment of samples generated from C-terminal region amplification of 
Cx43. The fasta  sequences of samples were aligned with the reference sequence available 
from NCBI website (blue higlight), in addition to the sequence of a normal DNA samples 
(pointed out by arrow head), using Clustal X software.
CHAPTER 5
DISCUSSION
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CHAPTER FIVE
DISCUSSION
The contribution of mutations in different genes like BRCA1 and BRCA2 
to the incidence and prevalence of breast cancer has been established worldwide 
and many more genes which could play role in the tumorigenesis of this disease 
at the primary or secondary level are unveiled continuously. Some of them 
directly influence BC risk, whereas others are involved in the general process of 
cancer growth and metastasis.  However, the role of these genes in pre-disposing 
Kashmiris to breast cancer is least explored represented by only a few studies. 
Kashmir, which lies at an altitude of 1800-2400km from the sea-level, is distinct 
from other areas in term of its location, culture, food habits and ethnicity. In the 
study population, consanguinity is the choice and the risk factors associated with 
the breast cancer in other regions like the nulliparity (Gail et al., 1989; Winer et 
al., 2000), consumption of alcohol (Longnecker et al., 1994) are lacking.
BRCA2 is one the well established breast cancer susceptibility gene 
mutated form of which when inherited strongly predisposes to breast cancer. In 
an attempt to screen the BRCA2 gene in Kashmiri population to establish its role 
in predisposing Kashmiri population to breast cancer, we have located four 
somatic mutations in BRCA2 gene at codon positions 846 (rs11571654), 868 
(Novel), 991 (rs1799944), 1131 (rs1801406) and one germ-line variation in the 
UTR region of exon 2 at contig position 13870572 (rs1799943). 
The amino-acid change at 991 position seen in 24% (12/50) of the 
patients is a mis-sense change and this change substitutes asparagine by aspartic 
acid. This amino-acid lies in the BRC1 repeat of exon 11, which constitutes one 
of those 4 repeats of BRCA2 protein that have been seen to be highly conserved 
in mammals (Bork et al. 1996; Bignell et al. 1997). These BRC repeats in 
BRCA2 protein helps in directly binding BRCA2 to RAD51, a critical protein for 
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DNA recombination and doube-stranded DNA repair (Benson et al., 1994; 
Donovan et al., 1994; Hays et al., 1995). The association of this mis-sense 
mutation to breast cancer susceptibility has been recently reported in Cyprus 
population (Maria et al., 2009). The authors have found significant association of 
this change with the increased risk of breast cancer. (p=0.01 and P=0.0076). A 
moderately strong association of this BRCA2 polymorphism with malignant 
melanoma risk has also been reported (p=0.02 after Bonferroni correction) 
(Debniak et al., 2007). In-silico prediction methods also suggest that this is a non-
tolerated amino-acid substitution within the limits of confidence in the 
alignments (Fackenthal et al., 2004). The role of this SNP in breast cancer has 
also been investigated in the Multi-ethnic cohort study and no association has 
been found (Freedman et al., 2004). Apart from this mis-sense mutation, a novel 
missense mutation is reported at position 846 replacing amino-acid proline by 
threonine. This novel missense mutation was seen in 88% of the Breast cancer 
patients and was always linked with another silent mutation at amino-acid 
position 826. This change was observed in the N-terminal region of exon 11 and 
lies very close to the highly conserved BRC1 repeat. This amino-acid change can 
be very significant as proline belonging to non-polar aliphatic group has been 
replaced by threonine belonging to a group of polar and uncharged amino-acids. 
The proline reduces the structural flexibility of protein at that position as the 
secondary amino (imino) group of proline is held in rigid conformation, thus this 
substitution can play important role in altering the functional properties of the 
protein. However, the strong association of this mis-sense mutation with another 
silent mutation at position 846 delivers something very strong and needs to 
further elucidated. It may be possible that the duo change is actually making 
carriers more susceptible to the breast cancer in this cohort of population. The 
germline variation G > A observed in the UTR region of the exon 2 was observed 
in 32% (16/50) of total patients. This variation observed is just 25 bases ahead of 
initiation codon in exon 2, thus there is a high probability that it may play an 
important role in RNA processing. Though this variant has been classified as a 
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variant of no clinical significance in the Breast Cancer Information Core 
Database (BIC), yet large and well controlled population based studies needs to 
be done to establish the full range of risks associated with this variant, as the 
association may be missed if only a small number of cancers are studied.
Apart from these mis-sense mutations, no deletion or insertion was seen. 
No mutation of any kind either germ-line or somatic was observed in exon 9, 18, 
20 and 25 screened. Nonetheless, the number of disease associated BRCA2 
mutations in Kashmiri sporadic breast cancer cases is very low and this study is 
comparable to the data available from other places. A mutational analysis of 
BRCA2 gene in North-Indian population has revealed no major sequence 
variation in BRCA2 except few mis-sense mutations (Saxena et al., 2002). They 
have not also reported any kind of deleterious or truncation mutation in any 
patient. 
The comparison of various clinico-epidemiological attributes of sporadic 
breast cancer patients to these somatic mutations had shown some kind of 
association although not significant with early onset and late onset breast cancer 
cases, menopausal status, advanced clinical stage (III and IV) of the disease. 
However there was no significant association seen with positive lymph node 
status and breast involved. Clinical tumor stage (III and IV) is a finding which 
assumes significance in view of the fact that it reflects poor prognosis. 
Decreased expression of Connexin 43 gap junctions is seen in breast 
cancer at various stages of progression and restoration of gap-junction 
intercellular communication by up-regulation of Connexin43 has been shown to
restore normal phenotypes (Laird et al., 1999; Mehta et al., 1991). Studies have 
shown that the tumor-suppressive capacity of individual connexins is very 
connexin-specific and tissue-specific, implying that mutational deactivation of 
certain connexins with particularly strong tumor-suppressive potency, but not 
others, may be etiologically implicated in tumorigenesis in tissues where they are 
expressed. Since Connexin 43 is predominantly expressed in gap junction protein 
in normal breast tissue and is a disease susceptibility gene for breast cancer, we 
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attempted to study whether Connexin 43 expression is impaired in neoplastic 
breast tissue due to any mutations in Kashmiri cohort of population. 
Compared to BRCA2, our results did not show any kind of variation 
whether somatic or germline in the coding region of Connexin 43 in any of the 
patients. As connexin genes have been suggested as tumor suppressor genes, it is 
expected that mutational deactivation of these genes during carcinogenesis can 
constitute strong evidence in favor of their tumor-suppressive capacity. In 
contrast, our results suggest that Cx43 gene mutations are rare in breast cancer. 
The lack of Cx43 mutations in human breast cancer samples makes it apparent 
that mutation of Cx43 is a rather rare event in tumor formation. Thus our study 
indicates that Connexin 43 is not down regulated in breast tumors due to any 
mutations. Instead some other regulatory mechanism like hypermethylation or 
mutation of the promoter region of the gene may play an important role in the 
down regulation of this gene.
Although some studies have reported mutations in Cx43 in advanced 
stage of the cancer (Dubina et al., 2002); on the contrary, we also did not report 
any kind of variation in the patients who were in the advanced stage of the 
disease. Thus our studies strongly implicate that mutational deactivation does not 
play any role in primary tumor formation or its metastasis in the breast. Our 
studies also imply (like Lee et al., 1991) that connexins can be described as class 
II tumor suppressors as the genes encoding connexins are not mutated while the 
protein expression levels are frequently altered, presumably due to the mutation 
of an upstream regulator or other factors. However it is debatable how far 
downstream connexins are from the primary assault and whether their regulation 
is a key player in carcinogenesis or simply a distant secondary effect.
In summary, the lack of Cx43 mutations and a high prevalence of somatic 
mis-sense mutations in BRCA2 suggest no role of Cx43 mutations in breast 
cancer predisposition in Kashmiri population but a definite involvement of 
BRCA2 mutations in the disease. Although no insertion or deletion was reported, 
but these mis-sense variations cannot be nullified as the prevailing polygenic 
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model of breast cancer risk suggests that a moderate number of genes, each 
conferring a small amount of risk alone (relative risk 1.3-1.5), together would 
combine multiplicatively, resulting in modest susceptibility to breast cancer 
(Antoniou et al., 2002). According to this model, more than 100 genes may 
contribute to breast cancer susceptibility. Each gene could have either common or 
rare variants and the women carrying more variant alleles would be at greater risk 
than those carrying fewer. Thus our results implicate that these somatic mis-sense 
variants may probably be contributing to the breast cancer susceptibility along 
with variations in other low penetrating genes in sporadic type of breast cancer in 
this cohort of population. 
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